<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml" xmlns:mml="http://www.w3.org/1998/Math/MathML">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#">
  <link rel="dns-prefetch" href="//d33xdlntwy0kbs.cloudfront.net"/>
  <link rel="dns-prefetch" href="//www.google.com"/>
  <link rel="dns-prefetch" href="//scholar.google.com"/>
  <link rel="dns-prefetch" href="//www.google-analytics.com"/>
  <link rel="dns-prefetch" href="//stats.g.doubleclick.net"/>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1"/>
  <link rel="shortcut icon" href="https://www.medrxiv.org/sites/default/files/images/favicon.ico" type="image/vnd.microsoft.icon"/>
  <link rel="alternate" type="application/pdf" title="Full Text (PDF)" href="/content/10.1101/2021.10.06.21264584v2.full.pdf"/>
  <link rel="alternate" type="text/plain" title="Full Text (Plain)" href="/content/10.1101/2021.10.06.21264584v2.full.txt"/>
  <link rel="alternate" type="application/vnd.ms-powerpoint" title="Powerpoint" href="/content/10.1101/2021.10.06.21264584v2.ppt"/>
  <meta name="type" content="article"/>
  <meta name="category" content="article"/>
  <meta name="HW.identifier" content="/medrxiv/early/2022/01/25/2021.10.06.21264584.atom"/>
  <meta name="HW.pisa" content="medrxiv;2021.10.06.21264584v2"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial"/>
  <meta name="DC.Identifier" content="10.1101/2021.10.06.21264584"/>
  <meta name="DC.Date" content="2022-01-25"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory Press"/>
  <meta name="DC.Rights" content="Â© 2022, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission."/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="Background Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen.

Methods Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose.

Results INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group.

Conclusion INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.

Trial Registration: [ClinicalTrials.gov][1] [NCT04336410][2]

Summary Two-milligram dose of INO-4800, a DNA-based vaccine encoding the SARS-CoV-2 spike protein, appears safe and well-tolerated and elicits humoral and cell-mediated immunity persisting to 6 months after a second dose. A third dose 6-10.5 months later significantly boosts immune responses.

### Competing Interest Statement

KAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals including salary and stock options, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received renumeration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.

### Clinical Trial

NCT04336410

### Funding Statement

This work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the institutional review board of each clinical site (The University of Pennsylvania Clinical Trials Unit in Philadelphia, PA; the Alliance for Multispecialty Research in Kansas City, MO; and the Alliance for Multispecialty Research in Lexington, KY.) and all participants provided written informed consent prior to enrollment. The trial was conducted under current Good Clinical Practices (GCP).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

The preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing.

 [1]: http://ClinicalTrials.gov
 [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04336410&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom"/>
  <meta name="DC.Contributor" content="Kimberly A. Kraynyak"/>
  <meta name="DC.Contributor" content="Elliott Blackwood"/>
  <meta name="DC.Contributor" content="Joseph Agnes"/>
  <meta name="DC.Contributor" content="Pablo Tebas"/>
  <meta name="DC.Contributor" content="Mary Giffear"/>
  <meta name="DC.Contributor" content="Dinah Amante"/>
  <meta name="DC.Contributor" content="Emma L. Reuschel"/>
  <meta name="DC.Contributor" content="Mansi Purwar"/>
  <meta name="DC.Contributor" content="Aaron Christensen-Quick"/>
  <meta name="DC.Contributor" content="Neiman Liu"/>
  <meta name="DC.Contributor" content="Viviane M. Andrade"/>
  <meta name="DC.Contributor" content="Malissa C. Diehl"/>
  <meta name="DC.Contributor" content="Snehal Wani"/>
  <meta name="DC.Contributor" content="Martyna Lupicka"/>
  <meta name="DC.Contributor" content="Albert Sylvester"/>
  <meta name="DC.Contributor" content="Matthew P. Morrow"/>
  <meta name="DC.Contributor" content="Patrick Pezzoli"/>
  <meta name="DC.Contributor" content="Trevor McMullan"/>
  <meta name="DC.Contributor" content="Abhijeet J. Kulkarni"/>
  <meta name="DC.Contributor" content="Faraz I. Zaidi"/>
  <meta name="DC.Contributor" content="Drew Frase"/>
  <meta name="DC.Contributor" content="Kevin Liaw"/>
  <meta name="DC.Contributor" content="Trevor R.F. Smith"/>
  <meta name="DC.Contributor" content="Stephanie J. Ramos"/>
  <meta name="DC.Contributor" content="John Ervin"/>
  <meta name="DC.Contributor" content="Mark Adams"/>
  <meta name="DC.Contributor" content="Jessica Lee"/>
  <meta name="DC.Contributor" content="Michael Dallas"/>
  <meta name="DC.Contributor" content="Ami Shah Brown"/>
  <meta name="DC.Contributor" content="Jacqueline E. Shea"/>
  <meta name="DC.Contributor" content="J. Joseph Kim"/>
  <meta name="DC.Contributor" content="David B. Weiner"/>
  <meta name="DC.Contributor" content="Kate E. Broderick"/>
  <meta name="DC.Contributor" content="Laurent M. Humeau"/>
  <meta name="DC.Contributor" content="Jean D. Boyer"/>
  <meta name="DC.Contributor" content="Mammen P. Mammen"/>
  <meta name="article:published_time" content="2022-01-25"/>
  <meta name="citation_title" content="SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial"/>
  <meta name="citation_abstract" lang="en" content="<h3>Abstract</h3>
<h3>Background</h3>
<p>Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen.</p><h3>Methods</h3>
<p>Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose.</p><h3>Results</h3>
<p>INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group.</p><h3>Conclusion</h3>
<p>INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.</p><p>Trial Registration: ClinicalTrials.govNCT04336410</p><h3>Summary</h3>
<p>Two-milligram dose of INO-4800, a DNA-based vaccine encoding the SARS-CoV-2 spike protein, appears safe and well-tolerated and elicits humoral and cell-mediated immunity persisting to 6 months after a second dose. A third dose 6-10.5 months later significantly boosts immune responses.</p>"/>
  <meta name="citation_journal_title" content="medRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory Press"/>
  <meta name="citation_publication_date" content="2022/01/01"/>
  <meta name="citation_mjid" content="medrxiv;2021.10.06.21264584v2"/>
  <meta name="citation_id" content="2021.10.06.21264584v2"/>
  <meta name="citation_public_url" content="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2"/>
  <meta name="citation_abstract_html_url" content="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2.abstract"/>
  <meta name="citation_full_html_url" content="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2.full"/>
  <meta name="citation_pdf_url" content="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2021.10.06.21264584"/>
  <meta name="citation_num_pages" content="44"/>
  <meta name="citation_article_type" content="Article"/>
  <meta name="citation_firstpage" content="2021.10.06.21264584"/>
  <meta name="citation_author" content="Kimberly A. Kraynyak"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Elliott Blackwood"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Joseph Agnes"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Pablo Tebas"/>
  <meta name="citation_author_institution" content="Hospital of the University of Pennsylvania"/>
  <meta name="citation_author" content="Mary Giffear"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Dinah Amante"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Emma L. Reuschel"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Mansi Purwar"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Aaron Christensen-Quick"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Neiman Liu"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Viviane M. Andrade"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Malissa C. Diehl"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Snehal Wani"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Martyna Lupicka"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Albert Sylvester"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Matthew P. Morrow"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Patrick Pezzoli"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Trevor McMullan"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Abhijeet J. Kulkarni"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Faraz I. Zaidi"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Drew Frase"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Kevin Liaw"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Trevor R.F. Smith"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Stephanie J. Ramos"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="John Ervin"/>
  <meta name="citation_author_institution" content="Alliance for Multispecialty Research"/>
  <meta name="citation_author" content="Mark Adams"/>
  <meta name="citation_author_institution" content="Alliance for Multispecialty Research"/>
  <meta name="citation_author" content="Jessica Lee"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Michael Dallas"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Ami Shah Brown"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Jacqueline E. Shea"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="J. Joseph Kim"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="David B. Weiner"/>
  <meta name="citation_author_institution" content="Vaccine and Immunotherapy Center, Wistar Institute"/>
  <meta name="citation_author" content="Kate E. Broderick"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Laurent M. Humeau"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author_email" content="laurent.humeau@inovio.com"/>
  <meta name="citation_author_email" content="kim.kraynyak@inovio.com"/>
  <meta name="citation_author" content="Jean D. Boyer"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_author" content="Mammen P. Mammen"/>
  <meta name="citation_author_institution" content="Inovio Pharmaceuticals, Plymouth Meeting"/>
  <meta name="citation_reference" content="Katz IT, Weintraub R, Bekker LG, Brandt AM. From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward. N Engl J Med 2021; 384:1281â3."/>
  <meta name="citation_reference" content="Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181:281â92.e6."/>
  <meta name="citation_reference" content="Carrillo J, Izquierdo-Useros N, Avila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun 2021; 538:187â91."/>
  <meta name="citation_reference" content="Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty 2021; 10:132."/>
  <meta name="citation_reference" content="Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol 2021; 12:714170."/>
  <meta name="citation_reference" content="Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020; 11:2601."/>
  <meta name="citation_reference" content="Gary EN, Weiner DB. DNA vaccines: prime time is now. Curr Opin Immunol 2020; 65:21â7."/>
  <meta name="citation_reference" content="Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the Cold Reality of mRNA Vaccine Stability. J Pharm Sci 2021; 110:997â1001."/>
  <meta name="citation_reference" content="Liu MA. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel) 2019; 7:37."/>
  <meta name="citation_reference" content="Middaugh CR, Evans RK, Montgomery DL, Casimiro DR. Analysis of plasmid DNA from a pharmaceutical perspective. J Pharm Sci 1998; 87:130â46."/>
  <meta name="citation_reference" content="Patel A, Walters J, Reuschel EL, et al. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv 2020."/>
  <meta name="citation_reference" content="Gooch KE, Smith TRF, Salguero FJ, et al. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model. Vaccine 2021; 39:4885â94."/>
  <meta name="citation_reference" content="Walters JN, Schouest B, Patel A, et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. bioRxiv 2021:2021.10.27.466163."/>
  <meta name="citation_reference" content="Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 2021; 31:100689."/>
  <meta name="citation_reference" content="Mammen MP, Tebas P, Agnes J, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv: the preprint server for health sciences 2021:2021.05.07.21256652."/>
  <meta name="citation_reference" content="Tebas P, Roberts CC, Muthumani K, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med 2017."/>
  <meta name="citation_reference" content="Tebas P, Kraynyak KA, Patel A, et al. Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis 2019; 220:400â10."/>
  <meta name="citation_reference" content="Aggarwal C, Cohen RB, Morrow MP, et al. Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. Vaccines (Basel) 2020; 8."/>
  <meta name="citation_reference" content="Chen M, Yuan Y, Zhou Y, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty 2021; 10:94."/>
  <meta name="citation_reference" content="Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021; 19:173."/>
  <meta name="citation_reference" content="Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nature reviews Immunology 2009; 9:185â94."/>
  <meta name="citation_reference" content="Prelog M. Differential approaches for vaccination from childhood to old age. Gerontology 2013; 59:230â9."/>
  <meta name="citation_reference" content="Kalimuddin S, Tham CYL, Qui M, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y) 2021; 2:682â8 e4."/>
  <meta name="citation_reference" content="Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nature reviews Immunology 2020; 20:529â36."/>
  <meta name="citation_reference" content="Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020; 183:996â1012 e19."/>
  <meta name="citation_reference" content="Andrade VM, Christensen-Quick A, Agnes J, et al. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. NPJ Vaccines 2021; 6:121."/>
  <meta name="twitter:title" content="SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial"/>
  <meta name="twitter:site" content="@medrxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.medrxiv.org/sites/default/files/images/medrxiv_logo_homepage7-5-small-test-up.png"/>
  <meta name="twitter:description" content="Background Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen.

Methods Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose.

Results INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group.

Conclusion INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.

Trial Registration: [ClinicalTrials.gov][1] [NCT04336410][2]

Summary Two-milligram dose of INO-4800, a DNA-based vaccine encoding the SARS-CoV-2 spike protein, appears safe and well-tolerated and elicits humoral and cell-mediated immunity persisting to 6 months after a second dose. A third dose 6-10.5 months later significantly boosts immune responses.

### Competing Interest Statement

KAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals including salary and stock options, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received renumeration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.

### Clinical Trial

NCT04336410

### Funding Statement

This work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the institutional review board of each clinical site (The University of Pennsylvania Clinical Trials Unit in Philadelphia, PA; the Alliance for Multispecialty Research in Kansas City, MO; and the Alliance for Multispecialty Research in Lexington, KY.) and all participants provided written informed consent prior to enrollment. The trial was conducted under current Good Clinical Practices (GCP).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

The preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing.

 [1]: http://ClinicalTrials.gov
 [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04336410&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom"/>
  <meta name="og-title" property="og:title" content="SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial"/>
  <meta name="og-url" property="og:url" content="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2"/>
  <meta name="og-site-name" property="og:site_name" content="medRxiv"/>
  <meta name="og-description" property="og:description" content="Background Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen.

Methods Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose.

Results INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group.

Conclusion INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.

Trial Registration: [ClinicalTrials.gov][1] [NCT04336410][2]

Summary Two-milligram dose of INO-4800, a DNA-based vaccine encoding the SARS-CoV-2 spike protein, appears safe and well-tolerated and elicits humoral and cell-mediated immunity persisting to 6 months after a second dose. A third dose 6-10.5 months later significantly boosts immune responses.

### Competing Interest Statement

KAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals including salary and stock options, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received renumeration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.

### Clinical Trial

NCT04336410

### Funding Statement

This work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the institutional review board of each clinical site (The University of Pennsylvania Clinical Trials Unit in Philadelphia, PA; the Alliance for Multispecialty Research in Kansas City, MO; and the Alliance for Multispecialty Research in Lexington, KY.) and all participants provided written informed consent prior to enrollment. The trial was conducted under current Good Clinical Practices (GCP).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

The preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing.

 [1]: http://ClinicalTrials.gov
 [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04336410&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom"/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.medrxiv.org/sites/default/files/images/medrxiv_logo_homepage7-5-small-test-up.png"/>
  <meta name="citation_date" content="2022-01-25"/>
  <meta name="description" content="medRxiv - The Preprint Server for Health Sciences"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/>
  <link rel="canonical" href="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2"/>
  <link rel="shortlink" href="https://www.medrxiv.org/node/465813"/>
  <title>
   SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial | medRxiv
  </title>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__7SC0i-kTgUlQGKuqbmyS18Sez8FDO-aG9FSHkGrLGl8__9Xf-fJpmF9h8tvWywQTaOzJzFLt4sEfx108Wh1gYmm0__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <link type="text/css" rel="stylesheet" href="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.css" media="all"/>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__JbFqFjYGp4Zx8gvmj6v5YmfNmbiFphGHPblyC9bfG5Y__OScmsb_1nSVmm_Ax3cJ5Rq7p081PahYkvF_YWQd5GtE__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <style type="text/css" media="all">
   /* &lt;![CDATA[ */
.panels-flexible-new .panels-flexible-region{padding:0}.panels-flexible-new .panels-flexible-region-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-new .panels-flexible-region-inside-first{padding-left:0}.panels-flexible-new .panels-flexible-region-inside-last{padding-right:0}.panels-flexible-new .panels-flexible-column{padding:0}.panels-flexible-new .panels-flexible-column-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-new .panels-flexible-column-inside-first{padding-left:0}.panels-flexible-new .panels-flexible-column-inside-last{padding-right:0}.panels-flexible-new .panels-flexible-row{padding:0 0 .5em;margin:0}.panels-flexible-new .panels-flexible-row-last{padding-bottom:0}.panels-flexible-column-new-main{float:left;width:99.0000%}.panels-flexible-new-inside{padding-right:0}.panels-flexible-new{width:auto}.panels-flexible-region-new-center{float:left;width:99.0000%}.panels-flexible-row-new-main-row-inside{padding-right:0}
/* ]]&gt; */
  </style>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__PWuQ_RYRTJ4BLEKsbWQeHysPg0gOQ3571ruQa_rXvAo__cj81oxtSGUe-AIO3tlkSBJPNpKP5ZgLdB8f8awBQsWU__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <style type="text/css" media="all">
   /* &lt;![CDATA[ */
#sliding-popup.sliding-popup-bottom,#sliding-popup.sliding-popup-bottom .eu-cookie-withdraw-banner,.eu-cookie-withdraw-tab{background:gray}#sliding-popup.sliding-popup-bottom.eu-cookie-withdraw-wrapper{background:transparent}#sliding-popup .popup-content #popup-text h1,#sliding-popup .popup-content #popup-text h2,#sliding-popup .popup-content #popup-text h3,#sliding-popup .popup-content #popup-text p,.eu-cookie-compliance-secondary-button,.eu-cookie-withdraw-tab{color:#fff !important}.eu-cookie-withdraw-tab{border-color:#fff}.eu-cookie-compliance-more-button{color:#fff !important}
/* ]]&gt; */
  </style>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__Wnlyen9qEpwh_Qaf9okEu4QdVGM0BDothxeqA6Nbvo8__EJmw6SZD9bYoS8jocCpPYS3JFRURpdzmuvJoAUNiI-g__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__MF4P_i8lKWP7DQR7GmjDAVTRBKLnzxvs1Dvton-Awi0__yi5OflfckG_G8-Li4dDQQ3wO9cGIcdPx_YQ7ZZDuj5w__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__2WBMox6sOrN42ss5lCnH7WWVRdFdJCxtTKnQJYRwTE4__yqNvNYLvMpjy3ffuJrjjm9uW2i-Me1c23KLYuWHaqio__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__5mxrBK4DuyvC2MR5irx_TzVn9c8vr4vIjmBXjunHfxE__rtQnXv8GOc-AsynbhzSlQBD_2lVxAkB6XEFUCK72qXc__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.css" media="all"/>
  <link type="text/css" rel="stylesheet" href="https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.css" media="all"/>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__BKYqkKToQ7EjirB7eIdMEH5521EU3da9IpoOs8Ex2XI__aSjVoX8giBmLhN2EbCgIGQJNu89Mh5aVu1LvI_gkJ7Y__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js">
  </script>
  <script type="text/javascript" src="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.js">
  </script>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__4Cn2dxvNlsJ-sHe6QOTLREaQvcqb0Yh0Zm9tTOHtQow__JeZEUjzbaj_yX6UjCI8eBbXy_J64ZVuoWmc2fSpLZHo__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js">
  </script>
  <script type="text/javascript" src="https://www.google.com/recaptcha/api.js?hl=en&render=explicit&onload=drupalRecaptchaOnload">
  </script>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__dGWpV57YWu3sX6UOe04RMH-iP9jSkEP7Ajt0caYXZZk__u2clNMaOO3LCM0tpFNpsQhnHrJ4_SUXG1gFb00eB1iU__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js">
  </script>
  <script type="text/javascript" async="async" src="https://scholar.google.com/scholar_js/casa.js">
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
/*!
 * yepnope1.5.4
 * (c) WTFPL, GPLv2
 */
(function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&amp;&amp;g(l.readyState)&amp;&amp;(u.r=o=1,!q&amp;&amp;h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&amp;&amp;m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&amp;&amp;y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&amp;&amp;(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&amp;&amp;(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&amp;&amp;h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&amp;&amp;!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&amp;&amp;"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&amp;&amp;!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&amp;&amp;(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f&lt;d;f++)g=a[f].split("="),(e=z[g.shift()])&amp;&amp;(c=e(c,g));for(f=0;f&lt;b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&amp;&amp;(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&amp;&amp;"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&amp;&amp;f.load(function(){k(),e&amp;&amp;e(i.origUrl,h,g),j&amp;&amp;j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&amp;&amp;b++;return b}(),a)a.hasOwnProperty(n)&amp;&amp;(!c&amp;&amp;!--m&amp;&amp;(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&amp;&amp;a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&amp;&amp;l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&amp;&amp;c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i&lt;a.length;i++)j=a[i],e(j)?g(j,0,l,0):w(j)?B(j):Object(j)===j&amp;&amp;h(j,l);else Object(a)===a&amp;&amp;h(a,l)},B.addPrefix=function(a,b){z[a]=b},B.addFilter=function(a){x.push(a)},B.errorTimeout=1e4,null==b.readyState&amp;&amp;b.addEventListener&amp;&amp;(b.readyState="loading",b.addEventListener("DOMContentLoaded",A=function(){b.removeEventListener("DOMContentLoaded",A,0),b.readyState="complete"},0)),a.yepnope=k(),a.yepnope.executeStack=h,a.yepnope.injectJs=function(a,c,d,e,i,j){var k=b.createElement("script"),l,o,e=e||B.errorTimeout;k.src=a;for(o in d)k.setAttribute(o,d[o]);c=j?h:c||f,k.onreadystatechange=k.onload=function(){!l&amp;&amp;g(k.readyState)&amp;&amp;(l=1,c(),k.onload=k.onreadystatechange=null)},m(function(){l||(l=1,c(1))},e),i?k.onload():n.parentNode.insertBefore(k,n)},a.yepnope.injectCss=function(a,c,d,e,g,i){var e=b.createElement("link"),j,c=i?h:c||f;e.href=a,e.rel="stylesheet",e.type="text/css";for(j in d)e.setAttribute(j,d[j]);g||(n.parentNode.insertBefore(e,n),m(c,0))}})(this,document);

//--&gt;&lt;!]]&gt;
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
yepnope({
  test: Modernizr.matchmedia,
  nope: '/sites/all/libraries/media-match/media.match.min.js'
});
//--&gt;&lt;!]]&gt;
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
var _prum=[['id', '52e95df3abe53d2e33000000'], ['mark', 'firstbyte',
      (new Date()).getTime()]]; (function() {
      var s=document.getElementsByTagName('script')[0],
      p=document.createElement('script');
      p.async='async'; p.src='//rum-static.pingdom.net/prum.min.js';s.parentNode.insertBefore(p,s);})();
//--&gt;&lt;!]]&gt;
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
if(typeof window.MathJax === "undefined") window.MathJax = { menuSettings: { zoom: "Click" } };
//--&gt;&lt;!]]&gt;
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
(function(i,s,o,g,r,a,m){i["GoogleAnalyticsObject"]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,"script","//www.google-analytics.com/analytics.js","ga");ga("create", "UA-141606356-1", {"cookieDomain":"auto"});ga("set", "page", location.pathname + location.search + location.hash);ga("send", "pageview");ga('create', 'UA-189672-38', 'auto', {'name': 'hwTracker'});
ga('set', 'anonymizeIp', true);
ga('hwTracker.send', 'pageview');
//--&gt;&lt;!]]&gt;
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
jQuery.extend(Drupal.settings,{"basePath":"\/","pathPrefix":"","ajaxPageState":{"theme":"jcore_1","theme_token":"FmUFcHXiT41k0nepEVjPn6oOz-IWiAGEeo5V8UNaydw"},"colorbox":{"opacity":"0.85","current":"{current} of {total}","previous":"\u00ab Prev","next":"Next \u00bb","close":"Close","maxWidth":"98%","maxHeight":"98%","fixed":true,"mobiledetect":true,"mobiledevicewidth":"480px"},"highwire":{"nid":"465813","apath":"\/medrxiv\/early\/2022\/01\/25\/2021.10.06.21264584.atom","pisa":"medrxiv;2021.10.06.21264584v2","processed":["highwire_math"],"markup":[{"requested":"full-text","variant":"full-text","view":"full","pisa":"medrxiv;2021.10.06.21264584v2"}],"modal_window_width":"560","share_modal_width":"560","share_modal_title":"Share this Article"},"jcarousel":{"ajaxPath":"\/jcarousel\/ajax\/views"},"instances":"{\u0022highwire_abstract_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:20,\u0022height\u0022:20,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-abstract-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022right center\u0022,\u0022my\u0022:\u0022left center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022shift\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter click \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_author_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-author-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022top center\u0022,\u0022my\u0022:\u0022bottom center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_reflinks_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022mimic\u0022:\u0022top center\u0022,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-ref-link-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022bottom left\u0022,\u0022my\u0022:\u0022top left\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022flip\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}}}","qtipDebug":"{\u0022leaveElement\u0022:0}","panel_ajax_tab":{"path":"sites\/all\/modules\/contrib\/panels_ajax_tab"},"disqus":{"domain":"medRxiv","url":"https:\/\/www.medrxiv.org\/content\/10.1101\/2021.10.06.21264584v2","title":"SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial","identifier":"node\/465813"},"panels_ajax_pane":{"new-28877068-b9cb-4641-830b-b6b4638c98bb":"{\u0022encrypted\u0022:\u0022{\\\u0022encrypted\\\u0022:\\\u0022e3AnexnLlcYqq5iGEVxGLqFwokOTjqkldeK5lfDEKweo\\\\\\\/nV3m4ts4PSncLWYr0EHsZt4I5vPyBsDG2H9u\\\\\\\/uVbUrL\\\\\\\/9nGQUREyz71EV7l8o0wDQeM1wuUmloHocLvzr5mp9s1k96aasQXaPcc2MuQY2YmbZvxz+utFsvhM9vSrcBTJb8V4ZFT9cMNxlEnGjdQrHqXnFJJuZ\\\\\\\/i+F1ushZc3Gj33LqThiD8UnYEpA66nm+H6SFSSN8+21Ahu+nns6AD0Ovn83VH9M7Vc\\\\\\\/yj9EXw3zo\\\\\\\/h0djbQF7HKbQWbxv8S5D8qcW12uoajq6uzD4mZQQO3qbDVo0hi7SEpziuDx+7Oli6qR8fLqA4Rp884JVSFR2pOo31QhmAkaTSru+gSYeIVmAusIYzd3rrl7uXNSZiAv19+gRnCkrQIi8svVgA54pFSp8GQIFU4T23LCzN52sxBZnePFbYJCFwGSom5F88J4fQHV7ahsa40pBYvO8P\\\\\\\/siPESVBdPg1onhBFEkZdC1NsQUOWlU0AuX4367yGC0YntBeJhqw1NP\\\\\\\/dct\\\\\\\/P6fQsYMpKvkImNsaUsJQJ\\\\\\\/j98BU9dQfODsnoss0h1Xjjy8QEL2W1mGm1oaRGByF7rnMisAxbUQZoq+sxFG6GWZNkALWZ+MxVWL2vPt5BF5AtWerppDEJ92L7+dCjOvwf\\\\\\\/rhZY+9834Y6czPkHhPLYeB+APdLw4icouCud84kGq5j\\\\\\\/QHe99688+Is4f7Me0zVoBtSgsiUNe92x1IE4PyJwR0gdQW8SQcQIOXHxtZmToFhBX6AxCKSojGYqJXSOYmG\\\\\\\/k528na7NfCKw9zR9iwATIlEj0VaLHDuhl4s2JRnI1\\\\\\\/GZ0SgXrntWFU5SBR6kPCAaZ\\\\\\\/aGAojBKutkBtYctOMAMIB2Iu6jNV+ojFkQZAeadl7LVnNqQzQbdDxzKAk5C7d\\\\\\\/L1T2SgUh0qEn\\\\\\\/gwa3OWSYnlbL2n1Nd2V847rFnHf+gNb31ZUXglkhpBWGNibitTjR7WLKCLYTBB7UIGfB7hdQKlarf2RCScgD9qKy5paWmyClaqO8NZiVTem+QrzpvPEAdQN8xcbshfherKtl5aCxCPiWpmwM929nJjCw59wibl1M49RZPyze7k+dgb\\\\\\\/VE9o3BCduQfMl7U\\\\\\\/Nk\\\\\\\/ONYmPPTnW4437X\\\\\\\/\\\\\\\/H\\\\\\\/Cb1DXVZUwHauODzVt5k7i5QH73I6jSsGPqB7JQj0f1O4rA1aYep7uBoSjY9Nc3P9Bh5ma5cLShYY5UzTKpb4MhuLDW+SX2HZxYaXw6wj0NWMt\\\\\\\/sd5rAqijO\\\\\\\/Xo1YxYI4Cn0nEwOuqCJ1sigPDw9W6Qp4mhxPnbyEjqsyzXeKcPZ17atuEeVRZ4VczZM1AV9irh9BkBq4cIg+rW2pBCrTsyU6hd+Rjx+9JV7c=\\\u0022,\\\u0022iv\\\u0022:\\\u0022yrEi02HwFbJS1DVpYRT9yg==\\\u0022,\\\u0022salt\\\u0022:\\\u0022f9d8845712f72c9fee5db7d9ff111eab\\\u0022}\u0022,\u0022hmac\u0022:\u00221b50755776ccaf01d865bb90a352da9903ee927a9fbdfa0a0225b3cecb85896e\u0022}"},"urlIsAjaxTrusted":{"\/content\/10.1101\/2021.10.06.21264584v2.full":true},"ws_fl":{"width":100,"height":21},"ws_gpo":{"size":"","annotation":"","lang":"","callback":"","width":300},"color":{"logo":"https:\/\/www.medrxiv.org\/sites\/default\/files\/medrxiv_internal_logo.png"},"highwire_list_expand":{"is_collapsed":"1"},"highwireResponsive":{"enquire_enabled":1,"breakpoints_configured":1,"breakpoints":{"zero":"all and (min-width: 0px)","xsmall":"all and (min-width: 380px)","narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}},"eu_cookie_compliance":{"popup_enabled":1,"popup_agreed_enabled":0,"popup_hide_agreed":0,"popup_clicking_confirmation":1,"popup_scrolling_confirmation":false,"popup_html_info":"\u003Cdiv\u003E\n  \u003Cdiv class =\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Cp\u003EWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EContinue\u003C\/button\u003E\n                    \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EFind out more\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","use_mobile_message":false,"mobile_popup_html_info":"\u003Cdiv\u003E\n  \u003Cdiv class =\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n          \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EContinue\u003C\/button\u003E\n                    \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EFind out more\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n","mobile_breakpoint":"768","popup_html_agreed":"\u003Cdiv\u003E\n  \u003Cdiv class=\u0022popup-content agreed\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Ch2\u003EThank you for accepting cookies\u003C\/h2\u003E\u003Cp\u003EYou can now hide this message or find out more about cookies.\u003C\/p\u003E    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022hide-popup-button eu-cookie-compliance-hide-button\u0022\u003EHide\u003C\/button\u003E\n              \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button-thank-you\u0022 \u003EMore info\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","popup_use_bare_css":false,"popup_height":"auto","popup_width":"100%","popup_delay":1000,"popup_link":"\/help\/cookie-policy","popup_link_new_window":1,"popup_position":null,"popup_language":"en","store_consent":false,"better_support_for_screen_readers":0,"reload_page":0,"domain":"","popup_eu_only_js":0,"cookie_lifetime":"365","cookie_session":false,"disagree_do_not_show_popup":0,"method":"default","whitelisted_cookies":"","withdraw_markup":"\u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-tab\u0022\u003EPrivacy settings\u003C\/button\u003E\n\u003Cdiv class=\u0022eu-cookie-withdraw-banner\u0022\u003E\n  \u003Cdiv class=\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Cp\u003E\u0026lt;h2\u0026gt;We use cookies on this site to enhance your user experience\u0026lt;\/h2\u0026gt;\u0026lt;p\u0026gt;You have given your consent for us to set cookies.\u0026lt;\/p\u0026gt;\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-button\u0022\u003EWithdraw consent\u003C\/button\u003E\n    \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n","withdraw_enabled":false},"googleanalytics":{"trackOutbound":1,"trackMailto":1,"trackDownload":1,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip","trackColorbox":1,"trackUrlFragments":1},"jnl_biorxiv_styles":{"defaultJCode":"medrxiv"},"omega":{"layouts":{"primary":"normal","order":["narrow","normal","wide"],"queries":{"narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}}}});
//--&gt;&lt;!]]&gt;
  </script>
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-465813 node-type-highwire-article context-content hw-default-jcode-medrxiv hw-article-type-article">
  <noscript>
   <iframe src="//www.googletagmanager.com/ns.html?id=GTM-P4HH5NV" height="0" width="0" style="display:none;visibility:hidden">
   </iframe>
  </noscript>
  <script type="text/javascript">
   (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&amp;l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-P4HH5NV');
  </script>
  <div id="skip-link">
   <a href="#main-content" class="element-invisible element-focusable">
    Skip to main content
   </a>
  </div>
  <div class="page clearfix page-box-shadows footer-borders panels-page panels-layout-jcore_2col" id="page">
   <header id="section-header" class="section section-header">
    <div id="zone-branding" class="zone zone-branding clearfix print-display-block container-30">
     <div class="grid-15 prefix-1 region region-branding print-display-block" id="region-branding">
      <div class="region-inner region-branding-inner">
       <div class="branding-data clearfix">
        <div class="logo-img">
         <a href="/" rel="home" class="" data-icon-position="" data-hide-link-title="0">
          <img alt="medRxiv" src="https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png"/>
         </a>
        </div>
       </div>
      </div>
     </div>
     <div class="grid-11 suffix-1 region region-branding-second print-hidden" id="region-branding-second">
      <div class="region-inner region-branding-second-inner">
       <div class="block block-system block-menu block-main-menu block-system-main-menu odd block-without-title" id="block-system-main-menu">
        <div class="block-inner clearfix">
         <div class="content clearfix">
          <nav class="menubar-nav">
           <ul class="menu" role="menu">
            <li class="first leaf" role="menuitem">
             <a href="/" title="" class="" data-icon-position="" data-hide-link-title="0">
              Home
             </a>
            </li>
            <li class="leaf" role="menuitem">
             <a href="/content/about-medrxiv" class="" data-icon-position="" data-hide-link-title="0">
              About
             </a>
            </li>
            <li class="leaf" role="menuitem">
             <a href="/submit-a-manuscript" class="" data-icon-position="" data-hide-link-title="0">
              Submit
             </a>
            </li>
            <li class="last leaf" role="menuitem">
             <a href="/content/alertsrss" title="" class="" data-icon-position="" data-hide-link-title="0">
              ALERTS / RSS
             </a>
            </li>
           </ul>
          </nav>
         </div>
        </div>
       </div>
       <div class="block block-panels-mini block-biorxiv-search-box block-panels-mini-biorxiv-search-box even block-without-title" id="block-panels-mini-biorxiv-search-box">
        <div class="block-inner clearfix">
         <div class="content clearfix">
          <div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_search_box">
           <div class="panel-panel panel-col">
            <div>
             <div class="panel-pane pane-highwire-seach-quicksearch">
              <div class="pane-content">
               <form class="highwire-quicksearch button-style-mini button-style-mini" action="/content/10.1101/2021.10.06.21264584v2.full" method="post" id="highwire-search-quicksearch-form-0" accept-charset="UTF-8">
                <div>
                 <div class="form-item form-item-label-invisible form-type-textfield form-item-keywords">
                  <label class="element-invisible" for="search_rightsidebar_keywords_1711690331">
                   Search for this keyword
                  </label>
                  <input placeholder="Search" type="text" id="search_rightsidebar_keywords_1711690331" name="keywords" value="" size="60" maxlength="128" class="form-text"/>
                 </div>
                 <div class="button-wrapper button-mini">
                  <span class="icon-search">
                  </span>
                  <input data-icon-only="1" data-font-icon="icon-search" data-icon-position="after" type="submit" id="search_rightsidebar_submit_2030145944" name="op" value="Search" class="form-submit"/>
                 </div>
                 <input type="hidden" name="form_build_id" value="form-prVcmbasDJkzEBRYAE6y2-u5KHaeofnKyt9G_bMMJt0"/>
                 <input type="hidden" name="form_id" value="highwire_search_quicksearch_form_0"/>
                </div>
               </form>
              </div>
             </div>
             <div class="panel-separator">
             </div>
             <div class="panel-pane pane-custom pane-2 advanced-search-link">
              <div class="pane-content">
               <a href="/search">
                Advanced Search
               </a>
              </div>
             </div>
            </div>
           </div>
          </div>
         </div>
        </div>
       </div>
      </div>
     </div>
    </div>
    <div id="zone-header" class="zone zone-header clearfix container-30">
    </div>
   </header>
   <section id="section-content" class="section section-content">
    <div id="zone-content" class="zone zone-content clearfix container-30">
     <div class="grid-28 suffix-1 prefix-1 region region-content" id="region-content">
      <div class="region-inner region-content-inner">
       <a id="main-content">
       </a>
       <div class="block block-system block-main block-system-main odd block-without-title" id="block-system-main">
        <div class="block-inner clearfix">
         <div class="content clearfix">
          <div class="panel-display panels-960-layout jcore-2col-layout">
           <div class="panel-row-wrapper clearfix">
            <div class="main-content-wrapper grid-17 suffix-1 alpha">
             <div class="panel-panel panel-region-content">
              <div class="inside">
               <div class="panel-pane pane-highwire-article-citation">
                <div class="pane-content">
                 <div class="highwire-article-citation highwire-citation-type-highwire-article node465813" data-node-nid="465813" id="node-465813--21024082773" data-pisa="medrxiv;2021.10.06.21264584v2" data-pisa-master="medrxiv;2021.10.06.21264584" data-apath="/medrxiv/early/2022/01/25/2021.10.06.21264584.atom" data-hw-author-tooltip-instance="">
                  <div class="highwire-cite highwire-cite-highwire-article highwire-citation-medrxiv-article-top clearfix has-author-tooltip">
                   <h1 class="highwire-cite-title" id="page-title">
                    SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
                   </h1>
                   <div class="highwire-cite-authors">
                    <span class="highwire-citation-authors">
                     <span class="highwire-citation-author first" data-delta="0">
                      <span class="nlm-given-names">
                       Kimberly A.
                      </span>
                      <span class="nlm-surname">
                       Kraynyak
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="1">
                      <span class="nlm-given-names">
                       Elliott
                      </span>
                      <span class="nlm-surname">
                       Blackwood
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="2">
                      <span class="nlm-given-names">
                       Joseph
                      </span>
                      <span class="nlm-surname">
                       Agnes
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="3">
                      <span class="nlm-given-names">
                       Pablo
                      </span>
                      <span class="nlm-surname">
                       Tebas
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="4">
                      <span class="nlm-given-names">
                       Mary
                      </span>
                      <span class="nlm-surname">
                       Giffear
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="5">
                      <span class="nlm-given-names">
                       Dinah
                      </span>
                      <span class="nlm-surname">
                       Amante
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="6">
                      <span class="nlm-given-names">
                       Emma L.
                      </span>
                      <span class="nlm-surname">
                       Reuschel
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="7">
                      <span class="nlm-given-names">
                       Mansi
                      </span>
                      <span class="nlm-surname">
                       Purwar
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="8">
                      <span class="nlm-given-names">
                       Aaron
                      </span>
                      <span class="nlm-surname">
                       Christensen-Quick
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="9">
                      <span class="nlm-given-names">
                       Neiman
                      </span>
                      <span class="nlm-surname">
                       Liu
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="10">
                      <span class="nlm-given-names">
                       Viviane M.
                      </span>
                      <span class="nlm-surname">
                       Andrade
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="11">
                      <span class="nlm-given-names">
                       Malissa C.
                      </span>
                      <span class="nlm-surname">
                       Diehl
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="12">
                      <span class="nlm-given-names">
                       Snehal
                      </span>
                      <span class="nlm-surname">
                       Wani
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="13">
                      <span class="nlm-given-names">
                       Martyna
                      </span>
                      <span class="nlm-surname">
                       Lupicka
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="14">
                      <span class="nlm-given-names">
                       Albert
                      </span>
                      <span class="nlm-surname">
                       Sylvester
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="15">
                      <span class="nlm-given-names">
                       Matthew P.
                      </span>
                      <span class="nlm-surname">
                       Morrow
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="16">
                      <span class="nlm-given-names">
                       Patrick
                      </span>
                      <span class="nlm-surname">
                       Pezzoli
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="17">
                      <span class="nlm-given-names">
                       Trevor
                      </span>
                      <span class="nlm-surname">
                       McMullan
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="18">
                      <span class="nlm-given-names">
                       Abhijeet J.
                      </span>
                      <span class="nlm-surname">
                       Kulkarni
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="19">
                      <span class="nlm-given-names">
                       Faraz I.
                      </span>
                      <span class="nlm-surname">
                       Zaidi
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="20">
                      <span class="nlm-given-names">
                       Drew
                      </span>
                      <span class="nlm-surname">
                       Frase
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="21">
                      <span class="nlm-given-names">
                       Kevin
                      </span>
                      <span class="nlm-surname">
                       Liaw
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="22">
                      <span class="nlm-given-names">
                       Trevor R.F.
                      </span>
                      <span class="nlm-surname">
                       Smith
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="23">
                      <span class="nlm-given-names">
                       Stephanie J.
                      </span>
                      <span class="nlm-surname">
                       Ramos
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="24">
                      <span class="nlm-given-names">
                       John
                      </span>
                      <span class="nlm-surname">
                       Ervin
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="25">
                      <span class="nlm-given-names">
                       Mark
                      </span>
                      <span class="nlm-surname">
                       Adams
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="26">
                      <span class="nlm-given-names">
                       Jessica
                      </span>
                      <span class="nlm-surname">
                       Lee
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="27">
                      <span class="nlm-given-names">
                       Michael
                      </span>
                      <span class="nlm-surname">
                       Dallas
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="28">
                      <span class="nlm-given-names">
                       Ami Shah
                      </span>
                      <span class="nlm-surname">
                       Brown
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="29">
                      <span class="nlm-given-names">
                       Jacqueline E.
                      </span>
                      <span class="nlm-surname">
                       Shea
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="30">
                      <span class="nlm-given-names">
                       J. Joseph
                      </span>
                      <span class="nlm-surname">
                       Kim
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="31">
                      <span class="nlm-given-names">
                       David B.
                      </span>
                      <span class="nlm-surname">
                       Weiner
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="32">
                      <span class="nlm-given-names">
                       Kate E.
                      </span>
                      <span class="nlm-surname">
                       Broderick
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="33">
                      <span class="nlm-given-names">
                       Laurent M.
                      </span>
                      <span class="nlm-surname">
                       Humeau
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="34">
                      <span class="nlm-given-names">
                       Jean D.
                      </span>
                      <span class="nlm-surname">
                       Boyer
                      </span>
                     </span>
                     ,
                     <span class="highwire-citation-author" data-delta="35">
                      <span class="nlm-given-names">
                       Mammen P.
                      </span>
                      <span class="nlm-surname">
                       Mammen
                      </span>
                      <span class="nlm-suffix">
                       Jr.
                      </span>
                     </span>
                    </span>
                   </div>
                   <div class="highwire-cite-metadata">
                    <span class="highwire-cite-metadata-doi highwire-cite-metadata">
                     <span class="label">
                      doi:
                     </span>
                     https://doi.org/10.1101/2021.10.06.21264584
                    </span>
                   </div>
                  </div>
                  <div id="hw-article-author-popups-node-465813--21024082773" style="display: none;">
                   <div class="author-tooltip-0">
                    <div class="author-tooltip-name">
                     Kimberly A. Kraynyak
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kimberly%2BA.%2BKraynyak%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Kraynyak%20KA&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AKimberly%2BA.%2BKraynyak%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-1">
                    <div class="author-tooltip-name">
                     Elliott Blackwood
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elliott%2BBlackwood%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Blackwood%20E&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AElliott%2BBlackwood%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-2">
                    <div class="author-tooltip-name">
                     Joseph Agnes
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joseph%2BAgnes%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Agnes%20J&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AJoseph%2BAgnes%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-3">
                    <div class="author-tooltip-name">
                     Pablo Tebas
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        3
                       </span>
                       <span class="nlm-institution">
                        Hospital of the University of Pennsylvania
                       </span>
                       , Philadelphia, PA,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Pablo%2BTebas%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Tebas%20P&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3APablo%2BTebas%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-4">
                    <div class="author-tooltip-name">
                     Mary Giffear
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mary%2BGiffear%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Giffear%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMary%2BGiffear%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-5">
                    <div class="author-tooltip-name">
                     Dinah Amante
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dinah%2BAmante%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Amante%20D&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ADinah%2BAmante%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-6">
                    <div class="author-tooltip-name">
                     Emma L. Reuschel
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Emma%2BL.%2BReuschel%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Reuschel%20EL&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AEmma%2BL.%2BReuschel%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-7">
                    <div class="author-tooltip-name">
                     Mansi Purwar
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mansi%2BPurwar%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Purwar%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMansi%2BPurwar%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-8">
                    <div class="author-tooltip-name">
                     Aaron Christensen-Quick
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aaron%2BChristensen-Quick%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Christensen-Quick%20A&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AAaron%2BChristensen-Quick%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-9">
                    <div class="author-tooltip-name">
                     Neiman Liu
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Neiman%2BLiu%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Liu%20N&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ANeiman%2BLiu%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-10">
                    <div class="author-tooltip-name">
                     Viviane M. Andrade
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Viviane%2BM.%2BAndrade%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Andrade%20VM&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AViviane%2BM.%2BAndrade%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-11">
                    <div class="author-tooltip-name">
                     Malissa C. Diehl
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Malissa%2BC.%2BDiehl%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Diehl%20MC&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMalissa%2BC.%2BDiehl%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-12">
                    <div class="author-tooltip-name">
                     Snehal Wani
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Snehal%2BWani%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Wani%20S&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ASnehal%2BWani%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-13">
                    <div class="author-tooltip-name">
                     Martyna Lupicka
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Martyna%2BLupicka%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Lupicka%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMartyna%2BLupicka%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-14">
                    <div class="author-tooltip-name">
                     Albert Sylvester
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Albert%2BSylvester%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Sylvester%20A&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AAlbert%2BSylvester%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-15">
                    <div class="author-tooltip-name">
                     Matthew P. Morrow
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BP.%2BMorrow%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Morrow%20MP&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMatthew%2BP.%2BMorrow%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-16">
                    <div class="author-tooltip-name">
                     Patrick Pezzoli
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patrick%2BPezzoli%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Pezzoli%20P&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3APatrick%2BPezzoli%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-17">
                    <div class="author-tooltip-name">
                     Trevor McMullan
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Trevor%2BMcMullan%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=McMullan%20T&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ATrevor%2BMcMullan%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-18">
                    <div class="author-tooltip-name">
                     Abhijeet J. Kulkarni
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abhijeet%2BJ.%2BKulkarni%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Kulkarni%20AJ&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AAbhijeet%2BJ.%2BKulkarni%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-19">
                    <div class="author-tooltip-name">
                     Faraz I. Zaidi
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Faraz%2BI.%2BZaidi%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Zaidi%20FI&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AFaraz%2BI.%2BZaidi%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-20">
                    <div class="author-tooltip-name">
                     Drew Frase
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Drew%2BFrase%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Frase%20D&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ADrew%2BFrase%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-21">
                    <div class="author-tooltip-name">
                     Kevin Liaw
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kevin%2BLiaw%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Liaw%20K&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AKevin%2BLiaw%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-22">
                    <div class="author-tooltip-name">
                     Trevor R.F. Smith
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Trevor%2BR.F.%2BSmith%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Smith%20TR&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ATrevor%2BR.F.%2BSmith%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-23">
                    <div class="author-tooltip-name">
                     Stephanie J. Ramos
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stephanie%2BJ.%2BRamos%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Ramos%20SJ&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AStephanie%2BJ.%2BRamos%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-24">
                    <div class="author-tooltip-name">
                     John Ervin
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        4
                       </span>
                       <span class="nlm-institution">
                        Alliance for Multispecialty Research
                       </span>
                       , Kansas City, MO,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=John%2BErvin%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Ervin%20J&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AJohn%2BErvin%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-25">
                    <div class="author-tooltip-name">
                     Mark Adams
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        5
                       </span>
                       <span class="nlm-institution">
                        Alliance for Multispecialty Research
                       </span>
                       , Lexington, KY,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mark%2BAdams%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Adams%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMark%2BAdams%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-26">
                    <div class="author-tooltip-name">
                     Jessica Lee
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessica%2BLee%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Lee%20J&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AJessica%2BLee%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-27">
                    <div class="author-tooltip-name">
                     Michael Dallas
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BDallas%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Dallas%20M&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMichael%2BDallas%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-28">
                    <div class="author-tooltip-name">
                     Ami Shah Brown
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ami%2BShah%2BBrown%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Brown%20AS&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AAmi%2BShah%2BBrown%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-29">
                    <div class="author-tooltip-name">
                     Jacqueline E. Shea
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jacqueline%2BE.%2BShea%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Shea%20JE&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AJacqueline%2BE.%2BShea%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-30">
                    <div class="author-tooltip-name">
                     J. Joseph Kim
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=J.%2BJoseph%2BKim%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Kim%20JJ&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AJ.%2BJoseph%2BKim%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-31">
                    <div class="author-tooltip-name">
                     David B. Weiner
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        2
                       </span>
                       <span class="nlm-institution">
                        Vaccine and Immunotherapy Center, Wistar Institute
                       </span>
                       , Philadelphia, PA, 19104,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David%2BB.%2BWeiner%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Weiner%20DB&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3ADavid%2BB.%2BWeiner%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-32">
                    <div class="author-tooltip-name">
                     Kate E. Broderick
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kate%2BE.%2BBroderick%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Broderick%20KE&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AKate%2BE.%2BBroderick%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-33">
                    <div class="author-tooltip-name">
                     Laurent M. Humeau
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Laurent%2BM.%2BHumeau%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Humeau%20LM&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link">
                      <a href="/search/author1%3ALaurent%2BM.%2BHumeau%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                     <li class="author-corresp-email-link last">
                      <span>
                       For correspondence:
                       <a href="mailto:laurent.humeau@inovio.com" class="" data-icon-position="" data-hide-link-title="0">
                        laurent.humeau@inovio.com
                       </a>
                       <a href="mailto:kim.kraynyak@inovio.com" class="" data-icon-position="" data-hide-link-title="0">
                        kim.kraynyak@inovio.com
                       </a>
                      </span>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-34">
                    <div class="author-tooltip-name">
                     Jean D. Boyer
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jean%2BD.%2BBoyer%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Boyer%20JD&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AJean%2BD.%2BBoyer%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                   <div class="author-tooltip-35">
                    <div class="author-tooltip-name">
                     Mammen P. Mammen
                     <span class="nlm-suffix">
                      Jr.
                     </span>
                    </div>
                    <div class="author-tooltip-affiliation">
                     <span class="author-tooltip-text">
                      <div class="author-affiliation">
                       <span class="nlm-sup">
                        1
                       </span>
                       <span class="nlm-institution">
                        Inovio Pharmaceuticals, Plymouth Meeting
                       </span>
                       , PA, 19462,
                       <span class="nlm-country">
                        USA
                       </span>
                      </div>
                     </span>
                    </div>
                    <ul class="author-tooltip-find-more">
                     <li class="author-tooltip-gs-link first">
                      <a href="/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mammen%2BP.%2BMammen%2B%3Cspan%2Bclass%3D%22nlm-suffix%22%3EJr.%3C/span%3E" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on Google Scholar
                      </a>
                     </li>
                     <li class="author-tooltip-pubmed-link">
                      <a href="/lookup/external-ref?access_num=Mammen%20MP&link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">
                       Find this author on PubMed
                      </a>
                     </li>
                     <li class="author-site-search-link last">
                      <a href="/search/author1%3AMammen%2BP.%2BMammen%2BJr." rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">
                       Search for this author on this site
                      </a>
                     </li>
                    </ul>
                   </div>
                  </div>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-highwire-panel-tabs pane-panels-ajax-tab-tabs">
                <div class="pane-content">
                 <div class="item-list">
                  <ul class="tabs inline panels-ajax-tab">
                   <li class="first">
                    <a href="/content/10.1101/2021.10.06.21264584v2" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_art" data-target-id="highwire_article_tabs" data-entity-context="node:465813" data-trigger="" data-url-enabled="1">
                     Abstract
                    </a>
                    <a href="/panels_ajax_tab/biorxiv_tab_art/node:465813/1" rel="nofollow" style="display:none" class="js-crawler-link">
                    </a>
                   </li>
                   <li>
                    <a href="/content/10.1101/2021.10.06.21264584v2.full-text" class="panels-ajax-tab-tab" data-panel-name="article_tab_full_text" data-target-id="highwire_article_tabs" data-entity-context="node:465813" data-trigger="full-text" data-url-enabled="1">
                     Full Text
                    </a>
                    <a href="/panels_ajax_tab/article_tab_full_text/node:465813/1" rel="nofollow" style="display:none" class="js-crawler-link">
                    </a>
                   </li>
                   <li>
                    <a href="/content/10.1101/2021.10.06.21264584v2.article-info" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_info" data-target-id="highwire_article_tabs" data-entity-context="node:465813" data-trigger="article-info" data-url-enabled="1">
                     Info/History
                    </a>
                    <a href="/panels_ajax_tab/biorxiv_tab_info/node:465813/1" rel="nofollow" style="display:none" class="js-crawler-link">
                    </a>
                   </li>
                   <li>
                    <a href="/content/10.1101/2021.10.06.21264584v2.article-metrics" class="panels-ajax-tab-tab" data-panel-name="article_tab_metrics" data-target-id="highwire_article_tabs" data-entity-context="node:465813" data-trigger="article-metrics" data-url-enabled="1">
                     Metrics
                    </a>
                    <a href="/panels_ajax_tab/article_tab_metrics/node:465813/1" rel="nofollow" style="display:none" class="js-crawler-link">
                    </a>
                   </li>
                   <li>
                    <a href="/content/10.1101/2021.10.06.21264584v2.external-links" class="panels-ajax-tab-tab" data-panel-name="article_tab_data_code" data-target-id="highwire_article_tabs" data-entity-context="node:465813" data-trigger="external-links" data-url-enabled="1">
                     Data/Code
                    </a>
                    <a href="/panels_ajax_tab/article_tab_data_code/node:465813/1" rel="nofollow" style="display:none" class="js-crawler-link">
                    </a>
                   </li>
                   <li class="last">
                    <a href="/content/10.1101/2021.10.06.21264584v2.full.pdf+html" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_pdf" data-target-id="highwire_article_tabs" data-entity-context="node:465813" data-trigger="full.pdf+html" data-url-enabled="1">
                     <i class="icon-file-alt">
                     </i>
                     Preview PDF
                    </a>
                    <a href="/panels_ajax_tab/biorxiv_tab_pdf/node:465813/1" rel="nofollow" style="display:none" class="js-crawler-link">
                    </a>
                   </li>
                  </ul>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-highwire-panel-tabs-container">
                <div class="pane-content">
                 <div data-panels-ajax-tab-preloaded="article_tab_full_text" id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container">
                  <div class="panels-ajax-tab-loading" style="display:none">
                   <img class="loading" src="https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif" alt="Loading" title="Loading"/>
                  </div>
                  <div class="panels-ajax-tab-wrap-article_tab_full_text">
                   <div class="panel-display panel-1col clearfix">
                    <div class="panel-panel panel-col">
                     <div>
                      <div class="panel-pane pane-highwire-markup">
                       <div class="pane-content">
                        <div class="highwire-markup">
                         <div xmlns="http://www.w3.org/1999/xhtml" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" class="content-block-markup" xmlns:xhtml="http://www.w3.org/1999/xhtml">
                          <div class="article fulltext-view">
                           <span class="highwire-journal-article-marker-start">
                           </span>
                           <div class="section abstract" id="abstract-1">
                            <h2 class="">
                             Abstract
                            </h2>
                            <div id="sec-1" class="subsection">
                             <p id="p-3">
                              <strong>
                               Background
                              </strong>
                              Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting the full-length spike antigen.
                             </p>
                            </div>
                            <div id="sec-2" class="subsection">
                             <p id="p-4">
                              <strong>
                               Methods
                              </strong>
                              Three dosage strengths of INO-4800 (0.5 mg, 1.0 mg, and 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10.5 months after the second dose.
                             </p>
                            </div>
                            <div id="sec-3" class="subsection">
                             <p id="p-5">
                              <strong>
                               Results
                              </strong>
                              INO-4800 appeared well tolerated, with no treatment-related serious adverse events. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+ T cells with lytic potential were significantly increased in the 2.0 mg dose group.
                             </p>
                            </div>
                            <div id="sec-4" class="subsection">
                             <p id="p-6">
                              <strong>
                               Conclusion
                              </strong>
                              INO-4800 was well tolerated in a 2-dose primary series and as a homologous booster in all adults, including the elderly. These results support further development of INO-4800 for use as a primary vaccine and as a booster.
                             </p>
                            </div>
                            <div id="sec-5" class="subsection">
                             <p id="p-7">
                              Trial Registration:
                              <a href="http://ClinicalTrials.gov">
                               ClinicalTrials.gov
                              </a>
                              <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04336410&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom">
                               NCT04336410
                              </a>
                             </p>
                            </div>
                            <div id="sec-6" class="subsection">
                             <p id="p-8">
                              <strong>
                               Summary
                              </strong>
                              Two-milligram dose of INO-4800, a DNA-based vaccine encoding the SARS-CoV-2 spike protein, appears safe and well-tolerated and elicits humoral and cell-mediated immunity persisting to 6 months after a second dose. A third dose 6-10.5 months later significantly boosts immune responses.
                             </p>
                            </div>
                           </div>
                           <div class="section" id="sec-7">
                            <h2 class="">
                             Introduction
                            </h2>
                            <p id="p-23">
                             Despite aggressive vaccination campaigns, most of the worldâs population remains unvaccinated and susceptible to COVID-19, the disease caused by SARS-CoV-2[
                             <a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">
                              1
                             </a>
                             ]. The urgent need remains for additional safe and effective vaccines that are affordable, scalable, and can be distributed to countries where the infrastructure may not be supportive of ultra-cold chain transport and storage.
                            </p>
                            <p id="p-24">
                             Attachment of SARS-CoV-2 to host cells is mediated by binding of the viral spike (S) protein to angiotensin converting enzyme 2 (ACE2) receptors on host cells[
                             <a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">
                              2
                             </a>
                             ]. Humoral responses against the spike protein prevent the virus from accessing host cells[
                             <a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">
                              3
                             </a>
                             ], and this strategy has led to the development of several vaccines targeting SARS-CoV-2 (reviewed by[
                             <a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">
                              4
                             </a>
                             ,
                             <a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">
                              5
                             </a>
                             ]).
                            </p>
                            <p id="p-25">
                             INO-4800 is an investigational optimized DNA vaccine, encoding the SARS-CoV-2 S protein[
                             <a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">
                              6
                             </a>
                             ], injected intradermally followed by in vivo electroporation[
                             <a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">
                              7
                             </a>
                             ]. This approach potentially offers several advantages, including induction of humoral and cellular immunity, favorable tolerability and thermal stability profiles, and ease of manufacture[
                             <a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">
                              8
                             </a>
                             ,
                             <a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">
                              9
                             </a>
                             ]. Plasmid DNA-based products in development by this sponsor have been shown to be stable at 2-8Â°C for 3-5 years, at room temperature (25Â°C) for least 1 year, and at 37Â°C for 1 month (unpublished data), and is in line with earlier reports on the stability of pharmaceutical grade plasmid DNA[
                             <a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">
                              10
                             </a>
                             ].
                            </p>
                            <p id="p-26">
                             Preclinical studies have shown INO-4800 to be immunogenic[
                             <a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">
                              6
                             </a>
                             ], with durable cellular and neutralizing antibody responses[
                             <a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">
                              11
                             </a>
                             ]. INO-4800 provided protection against viral challenge in non-human primates with no evidence of vaccine-enhanced disease[
                             <a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">
                              12
                             </a>
                             ], and elicited neutralizing antibodies reactive against multiple variants of concern (VOCs)[
                             <a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">
                              13
                             </a>
                             ].
                            </p>
                            <p id="p-27">
                             The preliminary safety and immunogenicity of INO-4800 in both Phase 1 and Phase 2 clinical studies have been previously reported[
                             <a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">
                              14
                             </a>
                             ,
                             <a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">
                              15
                             </a>
                             ]. The earlier analysis[
                             <a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">
                              14
                             </a>
                             ] demonstrated that two doses of INO-4800 administered one month apart were well tolerated in 38 healthy participants 18-50 years of age and induced neutralizing antibodies and/or T-cells. Here we describe the durability of that response at 6 months following the second dose, as well as the safety and immunogenicity of the 2-dose regimen in older and elderly participants, including following a subsequent homologous booster dose.
                            </p>
                           </div>
                           <div class="section" id="sec-8">
                            <h2 class="">
                             Methods
                            </h2>
                            <div id="sec-9" class="subsection">
                             <h3>
                              Trial Design and Participants
                             </h3>
                             <p id="p-28">
                              This Phase 1, open-label, multi-center trial (
                              <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04336410&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom">
                               NCT04336410
                              </a>
                              ) evaluated the safety, tolerability, and immunogenicity of INO-4800 injected intradermally (ID) followed by electroporation (EP). A total of 120 healthy participants without a known history of COVID-19 were assigned to receive a 0.5mg, 1.0mg, or 2.0mg dose of INO-4800 in a 2-dose regimen (weeks 0 and 4) and a subsequent optional booster dose no earlier than 8 weeks after dose 2. An equal number of participants were enrolled in each dose group (n=40) and further stratified by age groups [18-50 years of age; n=20, 51-64 years of age; n=10, and â¥65 years of age; n=10].
                             </p>
                             <p id="p-29">
                              The trial was approved by the institutional review board of each clinical site, all participants provided written informed consent prior to enrollment. The trial was conducted under current Good Clinical Practices (GCP).
                             </p>
                            </div>
                            <div id="sec-10" class="subsection">
                             <h3>
                              DNA Vaccine INO-4800
                             </h3>
                             <p id="p-30">
                              INO-4800 was previously described[
                              <a id="xref-ref-6-3" class="xref-bibr" href="#ref-6">
                               6
                              </a>
                              ,
                              <a id="xref-ref-14-3" class="xref-bibr" href="#ref-14">
                               14
                              </a>
                              ] and encodes the full-length sequence of the SARS-CoV-2 spike glycoprotein derived from the Wuhan strain based on an optimized synthetic sequence created using a proprietary algorithm. The final vaccine drug product, manufactured under Good Manufacturing Practices, was formulated at 10mg/mL in saline sodium citrate buffer.
                             </p>
                             <p id="p-31">
                              INO-4800 is injected ID followed by EP using the CELLECTRAÂ® 2000 device that generates a controlled electric field at the injection site to enhance the cellular uptake and expression of the DNA plasmid as previously described[
                              <a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">
                               16
                              </a>
                              ,
                              <a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">
                               17
                              </a>
                              ]. The device delivers a total of four electrical pulses per EP, each of 52 msec in duration, at current of 0.2 Amp and voltage of 40-200 per pulse.
                             </p>
                            </div>
                            <div id="sec-11" class="subsection">
                             <h3>
                              Endpoints
                             </h3>
                             <p id="p-32">
                              Primary safety endpoints included incidence of adverse events (AEs) using the âToxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trialâ including frequency and severity of injection site reactions. Primary immunological endpoints included the measurement of SARS-CoV-2 Spike glycoprotein antigen-specific binding antibodies as well as the measurement of antigen-specific cellular immune responses by IFN-Î³, ELISPOT and flow cytometry assays. Endpoints reflected in this publication are inclusive of 6 months after second dose (non-boosted participants) and, when applicable, 2 weeks after booster dose.
                             </p>
                            </div>
                            <div id="sec-12" class="subsection">
                             <h3>
                              Trial Procedures
                             </h3>
                             <p id="p-33">
                              Vaccine was administered in 0.1 ml ID injections in the deltoid followed by EP at the injection site. At each dosing visit, either a single injection for 0.5mg and 1.0mg dose groups or two injections for 2.0mg dose group were given, one in each deltoid.
                             </p>
                             <p id="p-34">
                              Forty participants 18-50 years were enrolled sequentially into 1.0mg and 2.0mg dose groups with a safety run-in period[
                              <a id="xref-ref-14-4" class="xref-bibr" href="#ref-14">
                               14
                              </a>
                              ]. The trial design was expanded to include older participants in all dosing groups (including a 0.5mg dose level). Upon favorable safety assessment review by an independent Data Safety Monitoring Board (DSMB) of Week 1 data for 0.5mg dose group participants aged 51-64 years and â¥ 65 years, enrollment of the corresponding age strata in the 1.0mg and subsequently 2.0mg dose groups was initiated.
                             </p>
                             <p id="p-35">
                              Participants were assessed for safety (complete blood count, serum chemistry, and urinalysis), including local and systemic AEs, at screening, Week 0 (Dose 1), next day phone call, and Weeks 1, 4 (Dose 2), 6, 8, 12, 28, 40 and 52. Blood immunology collections occurred at all clinic visits except Week 1. After the Week 12 visit, participants who consented to the optional booster dose were transitioned to an extended schedule of events to include the booster dose (Dose 3) and subsequent visits for safety at 2, 12, 24, 36, and 48 weeks following the booster dose with blood immunology collections at all clinic visits except 36 weeks.
                             </p>
                             <p id="p-36">
                              The DSMB reviewed laboratory and AE data for the participants up to 24 weeks after the second dose (non-boosted) and 2 weeks after booster dose.
                             </p>
                            </div>
                            <div id="sec-13" class="subsection">
                             <h3>
                              Protocol Eligibility
                             </h3>
                             <p id="p-37">
                              Key inclusion criteria included: healthy adults aged at least 18 years; and Body Mass Index of 18-30kg/m
                              <sup>
                               2
                              </sup>
                              at screening. Key exclusion criteria included: individuals in a current occupation with high risk of exposure to SARS-CoV-2; previous known exposure to SARS-CoV-2 or receipt of an investigational product for the prevention or treatment of COVID-19; autoimmune or immunosuppression as a result of underlying illness or treatment; hypersensitivity or severe allergic reactions to vaccines or drugs; and medical conditions that increased risk for severe COVID-19.
                             </p>
                            </div>
                            <div id="sec-14" class="subsection">
                             <h3>
                              Immunogenicity Assessment Methods
                             </h3>
                             <p id="p-38">
                              Samples were collected at timepoints described above with screening and pre-dose 1 samples considered baseline. Peripheral blood mononuclear cells (PBMCs) were collected as previously described[
                              <a id="xref-ref-14-5" class="xref-bibr" href="#ref-14">
                               14
                              </a>
                              ]. After isolation, PBMCs were stored in the vapor phase of a liquid nitrogen freezer until analysis, while serum samples were stored at â80Â°C. Eight participants were excluded from the immunogenicity analyses due to a positive ELISA titer to the SARS-CoV-2 nucleoprotein, suggesting SARS-CoV-2 infection
                             </p>
                            </div>
                            <div id="sec-15" class="subsection">
                             <h3>
                              SARS-CoV-2 Pseudovirus Neutralization Assay
                             </h3>
                             <p id="p-39">
                              Serum samples were measured using a pseudovirus neutralization assay as described previously[
                              <a id="xref-ref-15-2" class="xref-bibr" href="#ref-15">
                               15
                              </a>
                              ]. Data was reported as ID
                              <sub>
                               50
                              </sub>
                              , which is the reciprocal serum dilution resulting in 50% inhibition of infectivity by comparison to control wells with no serum samples added. Supplementary methods show additional information.
                             </p>
                            </div>
                            <div id="sec-16" class="subsection">
                             <h3>
                              SARS-CoV-2 Spike Enzyme-Linked Immunosorbent Assay (ELISA)
                             </h3>
                             <p id="p-40">
                              Binding antibodies to SARS-CoV-2 spike protein were measured by ELISA as described previously[
                              <a id="xref-ref-15-3" class="xref-bibr" href="#ref-15">
                               15
                              </a>
                              ]. SARS-CoV-2 spike antibody concentrations were determined by interpolation from a dilution curve of SARS-CoV-2 convalescent plasma with an assigned concentration of 20,000 Units/mL. Supplementary methods show additional information.
                             </p>
                            </div>
                            <div id="sec-17" class="subsection">
                             <h3>
                              SARS-CoV-2 Spike ELISpot Assay Description
                             </h3>
                             <p id="p-41">
                              The SARS-CoV-2 spike antigen-specific IFN-Î³ T-cell response was measured as described previously[
                              <a id="xref-ref-14-6" class="xref-bibr" href="#ref-14">
                               14
                              </a>
                              ]. Values were reported as the mean spot-forming units per million PBMCs across three triplicate wells after background subtraction using DMSO-only negative control wells. Supplementary methods show additional information.
                             </p>
                            </div>
                            <div id="sec-18" class="subsection">
                             <h3>
                              INO-4800 SARS-CoV-2 Spike Flow Cytometry Assays
                             </h3>
                             <p id="p-42">
                              PBMCs were also assessed in Intracellular Cytokine Staining (ICS) and Lytic Granule Loading (LGL) assays. The ICS assay was performed as previously described[
                              <a id="xref-ref-14-7" class="xref-bibr" href="#ref-14">
                               14
                              </a>
                              ]. The LGL assay was also performed as reported previously[
                              <a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">
                               18
                              </a>
                              ] following stimulation with overlapping peptides to the full-length spike protein to measure CD8+T cell activation and capacity to produce lytic proteins.
                             </p>
                            </div>
                            <div id="sec-19" class="subsection">
                             <h3>
                              Statistical Analysis
                             </h3>
                             <p id="p-43">
                              No formal power analysis was applicable to this trial. Descriptive statistics were used to summarize the safety endpoints based on the safety population: proportions of participants with AEs, through 6 months following dose 2 (non-boosted participants) or 2 weeks following booster dose. The safety population included all participants who received at least one dose of INO-4800 and were grouped by age and the dose of INO-4800. Post-hoc within subject analyses of post-vaccination minus pre-vaccination paired differences in SARS-CoV-2 neutralization and ELISA spike responses (on the natural log-scale, with a paired t-test), ELISpot responses (with Wilcoxon signed-rank tests), and flow assay responses (with Wilcoxon signed-rank tests) were performed.
                             </p>
                            </div>
                           </div>
                           <div class="section" id="sec-20">
                            <h2 class="">
                             Results
                            </h2>
                            <div id="sec-21" class="subsection">
                             <h3>
                              Trial Population Demographics
                             </h3>
                             <p id="p-44">
                              Between 06 April 2020 and 07 July 2020, 154 participants were screened and 120 enrolled into the trial (
                              <strong>
                               <a id="xref-fig-1-1" class="xref-fig" href="#F1">
                                Figure 1
                               </a>
                              </strong>
                              ). The median age was 50.5 years (range 18 to 86 years). Participants were 57.5% female (69/120) and 42.5% male (51/120) (
                              <strong>
                               <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">
                                Table 1
                               </a>
                              </strong>
                              ). Most participants were white (94.2%, 113/120).
                             </p>
                             <div id="F1" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F1.large.jpg?width=800&height=600&carousel=1" title="" class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Figure" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F1.medium.gif" width="440" height="205"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Figure" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F1.medium.gif" width="440" height="205"/>
                                   </noscript>
                                  </span>
                                 </a>
                                </div>
                               </div>
                               <ul class="highwire-figure-links inline">
                                <li class="download-fig first">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure1" data-icon-position="" data-hide-link-title="0">
                                  Download figure
                                 </a>
                                </li>
                                <li class="new-tab last">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                  Open in new tab
                                 </a>
                                </li>
                               </ul>
                              </div>
                             </div>
                             <div id="F2" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F2.large.jpg?width=800&height=600&carousel=1" title="Related systemic and local adverse events. Post First Dose, N=120 (N=40 in each dose group), Post Second Dose, N=117 (N=38 in the 0.5 mg dose group, N=40 in the 1.0 mg dose group and N=39 in the 2.0 mg dose group, and Post Third Dose, N=99 (N=33 in the 0.5 mg dose group, N=31 in the 1.0mg dose group and N=35 in the 2.0 mg dose group)" class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><span xmlns="http://www.w3.org/1999/xhtml" class="caption-title">Related systemic and local adverse events.</span> Post First Dose, N=120 (N=40 in each dose group), Post Second Dose, N=117 (N=38 in the 0.5 mg dose group, N=40 in the 1.0 mg dose group and N=39 in the 2.0 mg dose group, and Post Third Dose, N=99 (N=33 in the 0.5 mg dose group, N=31 in the 1.0mg dose group and N=35 in the 2.0 mg dose group)</div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Figure 2" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F2.medium.gif" width="440" height="196"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Figure 2" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F2.medium.gif" width="440" height="196"/>
                                   </noscript>
                                  </span>
                                 </a>
                                </div>
                               </div>
                               <ul class="highwire-figure-links inline">
                                <li class="download-fig first">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 2" data-icon-position="" data-hide-link-title="0">
                                  Download figure
                                 </a>
                                </li>
                                <li class="new-tab last">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                  Open in new tab
                                 </a>
                                </li>
                               </ul>
                              </div>
                              <div class="fig-caption" xmlns:xhtml="http://www.w3.org/1999/xhtml">
                               <span class="fig-label">
                                Figure 2
                               </span>
                               <span class="caption-title">
                                Related systemic and local adverse events.
                               </span>
                               <p id="p-45" class="first-child">
                                Post First Dose, N=120 (N=40 in each dose group), Post Second Dose, N=117 (N=38 in the 0.5 mg dose group, N=40 in the 1.0 mg dose group and N=39 in the 2.0 mg dose group, and Post Third Dose, N=99 (N=33 in the 0.5 mg dose group, N=31 in the 1.0mg dose group and N=35 in the 2.0 mg dose group)
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                             <div id="T1" class="table pos-float">
                              <div class="table-inline table-callout-links">
                               <div class="callout">
                                <span>
                                 View this table:
                                </span>
                                <ul class="callout-links">
                                 <li class="view-inline first">
                                  <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/467398/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">
                                   View inline
                                  </a>
                                 </li>
                                 <li class="view-popup">
                                  <a href="/highwire/markup/467398/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">
                                   View popup
                                  </a>
                                 </li>
                                 <li class="download-ppt last">
                                  <a href="/highwire/powerpoint/467398" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">
                                   Download powerpoint
                                  </a>
                                 </li>
                                </ul>
                               </div>
                              </div>
                              <div class="table-caption">
                               <span class="table-label">
                                Table 1
                               </span>
                               <p id="p-46" class="first-child">
                                Participant Demographics
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                            </div>
                            <div id="sec-22" class="subsection">
                             <h3>
                              Vaccine Safety and Tolerability
                             </h3>
                             <p id="p-47">
                              A total of 117 of 120 (97.5%) participants received both doses. One participant in the 2.0 mg group discontinued trial participation prior to receiving the second dose solely due to lack of transportation to the clinical site. Two participants in the 0.5 mg group did not receive the second dose due to exclusionary eligibility criteria (hypertension) having been determined following Dose 1; (
                              <strong>
                               <a id="xref-fig-1-2" class="xref-fig" href="#F1">
                                Figure 1
                               </a>
                              </strong>
                              ).
                             </p>
                             <p id="p-48">
                              Ninety-nine of 120 (82.5%) participants consented to and received the booster dose, approximately 6 to 10.5 months following the second dose. Reasons for not receiving booster dose included receipt of another SARS-CoV-2 vaccine (available under Emergency Use Authorization), new medical condition precluding participation (having had COVID-19, pregnancy or hypertension), or loss to follow-up.
                             </p>
                             <p id="p-49">
                              A total of 34 treatment-related local and systemic AEs were reported by 18 participants. Thirty-one AEs were Grade 1 (mild) in severity and comprised mostly injection site reactions. Three treatment-related Grade 2 (moderate) AEs were reported as lethargy, abdominal pain, and injection site pruritus. There were no febrile reactions reported. No participants discontinued due to AEs. No treatment-related SAEs were reported. There were no abnormal laboratory values that were deemed treatment-related and clinically significant by the Investigators. There was no increase in the number of participants who experienced related AEs in the 2.0 mg group (12.5%, 5/40), compared to that in the 1.0 mg group (15%, 6/40) or the 0.5 mg group (17.5%, 7/40). In addition, there was no appreciable increase in the frequency of AEs with the second or booster doses when compared to the first dose (
                              <strong>
                               <a id="xref-fig-2-1" class="xref-fig" href="#F2">
                                Figure 2
                               </a>
                              </strong>
                              ). A decrease in frequency of treatment-related AEs in the older and elderly age cohorts was observed when compared to the younger age group (
                              <strong>
                               <a id="xref-table-wrap-5-1" class="xref-table" href="#T5">
                                Supplementary Table 4
                               </a>
                              </strong>
                              ).
                             </p>
                            </div>
                            <div id="sec-23" class="subsection">
                             <h3>
                              INO-4800 induces durable humoral immune responses capable of being boosted
                             </h3>
                             <p id="p-50">
                              Induction of antibodies against SARS-CoV-2 following vaccination with INO-4800 was measured from sera. The functionality of antibodies was assessed using a pseudovirus neutralization assay. All dose groups induced neutralizing antibodies that peaked two weeks post second dose (GMTs-14.9, 19.1, 54.1 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively) (
                              <strong>
                               <a id="xref-fig-3-1" class="xref-fig" href="#F3">
                                Figure 3A
                               </a>
                               , left panel,
                               <a id="xref-table-wrap-2-1" class="xref-table" href="#T2">
                                Supplementary Table 1
                               </a>
                              </strong>
                              ). These increased responses were statistically significant over baseline in the 2.0 mg dose group for each time point through study week 28, approximately 6 months after dose 2 (
                              <strong>
                               <a id="xref-fig-3-2" class="xref-fig" href="#F3">
                                Figure 3A
                               </a>
                               , table
                              </strong>
                              ). Following administration of a booster dose, statistically significant increases over pre-boost titers were observed in all dose groups (GMTs-58.7, 76.1, 100 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively; all P<0.001) (
                              <strong>
                               <a id="xref-fig-3-3" class="xref-fig" href="#F3">
                                Figure 3A
                               </a>
                               , right panel,
                               <a id="xref-table-wrap-2-2" class="xref-table" href="#T2">
                                Supplementary Table 1
                               </a>
                              </strong>
                              ). The 2.0 mg dose group had a 12.8 (95%CI 6.3, 26.0) geometric fold rise (GMFR) over pre-boost titers, the highest of any dose group. Neutralization titers by participant age are shown in
                              <strong>
                               <a id="xref-fig-6-1" class="xref-fig" href="#F6">
                                Supplementary Figure 1A
                               </a>
                               ;
                              </strong>
                              GMTs were numerically lower in the older age groups but statistically significantly higher than baseline at week 6 in the 2.0 mg dose group. Plasma samples from convalescent samples had a GMT of 922 and ranged from 10 to 13,249
                              <strong>
                               (
                               <a id="xref-fig-7-1" class="xref-fig" href="#F7">
                                Supplementary Figure 2A
                               </a>
                               )
                              </strong>
                              .
                             </p>
                             <div id="F6" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-12.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces antibodies to SARS-CoV-2 across all age groups 18-50, 51-64 and â¥65 year olds A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID50) is plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=26 (n=12 18-50 year olds, n=9 51-64 year olds and n=5 â¥65 year olds), n=21 (n=11 18-50 year olds, n=6, 51-64 year olds and n=4 â¥65 year olds) and n=27 (n=15 18-50 year olds, n=5 51-64 year olds and n=7 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=31 (n=16 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=29 (n=13 18-50 year olds, n=8, 51-64 year olds and n=8 â¥65 year olds) and n=32 (n=15 18-50 year olds, n=7 51-64 year olds and n=10 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the horizontal line represents the GMT and the whiskers extend to the 95%CI values. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml">INO-4800 induces antibodies to SARS-CoV-2 across all age groups 18-50, 51-64 and â¥65 year olds A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID<sub>50</sub>) is plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=26 (n=12 18-50 year olds, n=9 51-64 year olds and n=5 â¥65 year olds), n=21 (n=11 18-50 year olds, n=6, 51-64 year olds and n=4 â¥65 year olds) and n=27 (n=15 18-50 year olds, n=5 51-64 year olds and n=7 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=31 (n=16 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=29 (n=13 18-50 year olds, n=8, 51-64 year olds and n=8 â¥65 year olds) and n=32 (n=15 18-50 year olds, n=7 51-64 year olds and n=10 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the horizontal line represents the GMT and the whiskers extend to the 95%CI values. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Supplementary Figure 1:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-12.medium.gif" width="440" height="374"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Supplementary Figure 1:" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-12.medium.gif" width="440" height="374"/>
                                   </noscript>
                                  </span>
                                 </a>
                                 <ul class="highwire-figure-links inline">
                                  <li class="download-fig first">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-12.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download " data-icon-position="" data-hide-link-title="0">
                                    Download figure
                                   </a>
                                  </li>
                                  <li class="new-tab last">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-12.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                    Open in new tab
                                   </a>
                                  </li>
                                 </ul>
                                </div>
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-13.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces antibodies to SARS-CoV-2 across all age groups 18-50, 51-64 and â¥65 year olds A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID50) is plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=26 (n=12 18-50 year olds, n=9 51-64 year olds and n=5 â¥65 year olds), n=21 (n=11 18-50 year olds, n=6, 51-64 year olds and n=4 â¥65 year olds) and n=27 (n=15 18-50 year olds, n=5 51-64 year olds and n=7 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=31 (n=16 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=29 (n=13 18-50 year olds, n=8, 51-64 year olds and n=8 â¥65 year olds) and n=32 (n=15 18-50 year olds, n=7 51-64 year olds and n=10 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the horizontal line represents the GMT and the whiskers extend to the 95%CI values. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml">INO-4800 induces antibodies to SARS-CoV-2 across all age groups 18-50, 51-64 and â¥65 year olds A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID<sub>50</sub>) is plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=26 (n=12 18-50 year olds, n=9 51-64 year olds and n=5 â¥65 year olds), n=21 (n=11 18-50 year olds, n=6, 51-64 year olds and n=4 â¥65 year olds) and n=27 (n=15 18-50 year olds, n=5 51-64 year olds and n=7 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=31 (n=16 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=29 (n=13 18-50 year olds, n=8, 51-64 year olds and n=8 â¥65 year olds) and n=32 (n=15 18-50 year olds, n=7 51-64 year olds and n=10 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the horizontal line represents the GMT and the whiskers extend to the 95%CI values. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Supplementary Figure 1:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-13.medium.gif" width="440" height="321"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Supplementary Figure 1:" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-13.medium.gif" width="440" height="321"/>
                                   </noscript>
                                  </span>
                                 </a>
                                 <ul class="highwire-figure-links inline">
                                  <li class="download-fig first">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-13.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download " data-icon-position="" data-hide-link-title="0">
                                    Download figure
                                   </a>
                                  </li>
                                  <li class="new-tab last">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F6/graphic-13.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                    Open in new tab
                                   </a>
                                  </li>
                                 </ul>
                                </div>
                               </div>
                              </div>
                              <div class="fig-caption">
                               <span class="fig-label">
                                Supplementary Figure 1:
                               </span>
                               <p id="p-78" class="first-child">
                                INO-4800 induces antibodies to SARS-CoV-2 across all age groups 18-50, 51-64 and â¥65 year olds A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID
                                <sub>
                                 50
                                </sub>
                                ) is plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=26 (n=12 18-50 year olds, n=9 51-64 year olds and n=5 â¥65 year olds), n=21 (n=11 18-50 year olds, n=6, 51-64 year olds and n=4 â¥65 year olds) and n=27 (n=15 18-50 year olds, n=5 51-64 year olds and n=7 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=31 (n=16 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=29 (n=13 18-50 year olds, n=8, 51-64 year olds and n=8 â¥65 year olds) and n=32 (n=15 18-50 year olds, n=7 51-64 year olds and n=10 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the horizontal line represents the GMT and the whiskers extend to the 95%CI values. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                             <div id="F7" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F7.large.jpg?width=800&height=600&carousel=1" title="Antibody responses in SARS-CoV-2 convalescent donors. Plasma from convalescent donors (n=38) was obtained. A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID50) is plotted. B) Binding antibody concentrations to the Spike trimer were measured using ELISA." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml"><span class="caption-title">Antibody responses in SARS-CoV-2 convalescent donors.</span> Plasma from convalescent donors (n=38) was obtained. A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID<sub>50</sub>) is plotted. B) Binding antibody concentrations to the Spike trimer were measured using ELISA.</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Supplementary Figure 2:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F7.medium.gif" width="440" height="211"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Supplementary Figure 2:" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F7.medium.gif" width="440" height="211"/>
                                   </noscript>
                                  </span>
                                 </a>
                                </div>
                               </div>
                               <ul class="highwire-figure-links inline">
                                <li class="download-fig first">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F7.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Supplementary Figure 2:" data-icon-position="" data-hide-link-title="0">
                                  Download figure
                                 </a>
                                </li>
                                <li class="new-tab last">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F7.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                  Open in new tab
                                 </a>
                                </li>
                               </ul>
                              </div>
                              <div class="fig-caption">
                               <span class="fig-label">
                                Supplementary Figure 2:
                               </span>
                               <span class="caption-title">
                                Antibody responses in SARS-CoV-2 convalescent donors.
                               </span>
                               <p id="p-79" class="first-child">
                                Plasma from convalescent donors (n=38) was obtained. A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID
                                <sub>
                                 50
                                </sub>
                                ) is plotted. B) Binding antibody concentrations to the Spike trimer were measured using ELISA.
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                             <div id="F3" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F3.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces antibodies to SARS-CoV-2. A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID50) is plotted. The dotted line represents the lowest dilution tested in the assay (1:20). The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=33, n=26 and n=31 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=29 and n=32 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml"><span class="caption-title">INO-4800 induces antibodies to SARS-CoV-2.</span> A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID<sub>50</sub>) is plotted. The dotted line represents the lowest dilution tested in the assay (1:20). The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=33, n=26 and n=31 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=29 and n=32 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the box extends from the 25<sup>th</sup> to the 75<sup>th</sup> percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Figure 3" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F3.medium.gif" width="440" height="309"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Figure 3" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F3.medium.gif" width="440" height="309"/>
                                   </noscript>
                                  </span>
                                 </a>
                                </div>
                               </div>
                               <ul class="highwire-figure-links inline">
                                <li class="download-fig first">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 3" data-icon-position="" data-hide-link-title="0">
                                  Download figure
                                 </a>
                                </li>
                                <li class="new-tab last">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                  Open in new tab
                                 </a>
                                </li>
                               </ul>
                              </div>
                              <div class="fig-caption">
                               <span class="fig-label">
                                Figure 3
                               </span>
                               <span class="caption-title">
                                INO-4800 induces antibodies to SARS-CoV-2.
                               </span>
                               <p id="p-51" class="first-child">
                                A) Functional antibodies were assessed using a pseudovirus neutralization assay. The inhibition dilution where 50% neutralization occurs (ID
                                <sub>
                                 50
                                </sub>
                                ) is plotted. The dotted line represents the lowest dilution tested in the assay (1:20). The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=33, n=26 and n=31 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Binding antibody concentrations to the Spike trimer were measured using ELISA. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=29 and n=32 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. Open symbols represent individual participants, the box extends from the 25
                                <sup>
                                 th
                                </sup>
                                to the 75
                                <sup>
                                 th
                                </sup>
                                percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Paired t test was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                             <p id="p-52">
                              Antibodies to the spike trimer protein were measured in a binding ELISA. All three groups exhibited binding antibodies that peaked four weeks following dose 2 (Geometric Mean Titers, GMTs-428.5, 595.9, 678.0 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively) (
                              <strong>
                               <a id="xref-fig-3-4" class="xref-fig" href="#F3">
                                Figure 3B
                               </a>
                               , left panel,
                               <a id="xref-table-wrap-3-1" class="xref-table" href="#T3">
                                Supplementary Table 2
                               </a>
                              </strong>
                              ). Increases over baseline were observed in all participants who received the 2.0 mg dose, but not in all participants in the other groups, and GMTs were statistically significantly higher than baseline 6 months following dose 2 (GMTs-250.1, 215.3, 407.2 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively; all P<0.026).
                             </p>
                             <p id="p-53">
                              Following administration of a booster dose, statistically significant increases over pre-boost titers were observed in all dose groups (GMTs-1963.8, 3685, 5953 in the 0.5 mg, 1.0 mg and 2.0 mg dose groups, respectively; all Pâ¤0.007) (
                              <strong>
                               <a id="xref-fig-3-5" class="xref-fig" href="#F3">
                                Figure 3B
                               </a>
                               , right panel,
                               <a id="xref-table-wrap-3-2" class="xref-table" href="#T3">
                                Supplementary Table 2
                               </a>
                              </strong>
                              ). The 2.0 mg dose group had a 20.8 (95%CI 13.9, 31.2) GMFR over pre-boost titers which was the highest of any dose group. ELISA binding titers by participant age are shown in
                              <strong>
                               <a id="xref-fig-6-2" class="xref-fig" href="#F6">
                                Supplementary Figure 1B
                               </a>
                               .
                              </strong>
                              Plasma samples from convalescent samples had a GMT of 19,444 and ranged from 330 to 247,200
                              <strong>
                               (
                               <a id="xref-fig-7-2" class="xref-fig" href="#F7">
                                Supplementary Figure 2B
                               </a>
                               )
                              </strong>
                              .
                             </p>
                            </div>
                            <div id="sec-24" class="subsection">
                             <h3>
                              INO-4800 induces cellular immune responses capable of being boosted
                             </h3>
                             <p id="p-54">
                              Interferon-gamma (IFNÎ³) ELISpot was performed on PBMCs. Increases in spot forming units (SFU) per million PBMCs over baseline are shown in
                              <strong>
                               <a id="xref-fig-4-1" class="xref-fig" href="#F4">
                                Figure 4A
                               </a>
                               , left panel
                              </strong>
                              . Magnitudes of IFNÎ³ peaked at week 6 for the 0.5 mg and 2.0 mg dose groups (median 19.4 and 43.3, respectively) and at week 8 for the 1.0 mg dose group (median 17.8). Six months following dose 2, magnitudes remained high in the 2.0 mg dose group (median 19.6). Of note, magnitudes in the 1.0 mg and 2.0 mg dose groups were statistically significantly increased following the booster dose (P=0.018 and P=0.008, respectively) (
                              <strong>
                               <a id="xref-fig-4-2" class="xref-fig" href="#F4">
                                Figure 4A
                               </a>
                               , right panel
                              </strong>
                              ). The 2.0 mg dose group had a difference in medians of 10 following the booster, resulting in the highest post-boost increase of any dose group. ELISpot responses by participant age are shown in
                              <strong>
                               <a id="xref-fig-8-1" class="xref-fig" href="#F8">
                                Supplementary Figure 3A
                               </a>
                               .
                              </strong>
                             </p>
                             <div id="F8" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-15.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces cellular responses to SARS-CoV-2 Spike across all age groups (18-50, 51-64, and â¥65 years). A) Longitudinal increases in spike antigen specific spot forming units per 106 PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=34 (n=19 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=24 (n=10 18-50 year olds, n=7, 51-64 year olds and n=7 â¥65 year olds) and n=28 (n=14 18-50 year olds, n=5 51-64 year olds and n=9 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Example gating strategy for flow cytometry assays. C-D) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds). Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml">INO-4800 induces cellular responses to SARS-CoV-2 Spike across all age groups (18-50, 51-64, and â¥65 years). A) Longitudinal increases in spike antigen specific spot forming units per 10<sup>6</sup> PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=34 (n=19 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=24 (n=10 18-50 year olds, n=7, 51-64 year olds and n=7 â¥65 year olds) and n=28 (n=14 18-50 year olds, n=5 51-64 year olds and n=9 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Example gating strategy for flow cytometry assays. C-D) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds). Open symbols represent individual participants, the box extends from the 25<sup>th</sup> to the 75<sup>th</sup> percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Supplementary Figure 3:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-15.medium.gif" width="351" height="440"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Supplementary Figure 3:" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-15.medium.gif" width="351" height="440"/>
                                   </noscript>
                                  </span>
                                 </a>
                                 <ul class="highwire-figure-links inline">
                                  <li class="download-fig first">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-15.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download " data-icon-position="" data-hide-link-title="0">
                                    Download figure
                                   </a>
                                  </li>
                                  <li class="new-tab last">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-15.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                    Open in new tab
                                   </a>
                                  </li>
                                 </ul>
                                </div>
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-16.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces cellular responses to SARS-CoV-2 Spike across all age groups (18-50, 51-64, and â¥65 years). A) Longitudinal increases in spike antigen specific spot forming units per 106 PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=34 (n=19 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=24 (n=10 18-50 year olds, n=7, 51-64 year olds and n=7 â¥65 year olds) and n=28 (n=14 18-50 year olds, n=5 51-64 year olds and n=9 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Example gating strategy for flow cytometry assays. C-D) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds). Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml">INO-4800 induces cellular responses to SARS-CoV-2 Spike across all age groups (18-50, 51-64, and â¥65 years). A) Longitudinal increases in spike antigen specific spot forming units per 10<sup>6</sup> PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=34 (n=19 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=24 (n=10 18-50 year olds, n=7, 51-64 year olds and n=7 â¥65 year olds) and n=28 (n=14 18-50 year olds, n=5 51-64 year olds and n=9 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Example gating strategy for flow cytometry assays. C-D) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds). Open symbols represent individual participants, the box extends from the 25<sup>th</sup> to the 75<sup>th</sup> percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Supplementary Figure 3:" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-16.medium.gif" width="335" height="440"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Supplementary Figure 3:" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-16.medium.gif" width="335" height="440"/>
                                   </noscript>
                                  </span>
                                 </a>
                                 <ul class="highwire-figure-links inline">
                                  <li class="download-fig first">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-16.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download " data-icon-position="" data-hide-link-title="0">
                                    Download figure
                                   </a>
                                  </li>
                                  <li class="new-tab last">
                                   <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F8/graphic-16.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                    Open in new tab
                                   </a>
                                  </li>
                                 </ul>
                                </div>
                               </div>
                              </div>
                              <div class="fig-caption">
                               <span class="fig-label">
                                Supplementary Figure 3:
                               </span>
                               <p id="p-80" class="first-child">
                                INO-4800 induces cellular responses to SARS-CoV-2 Spike across all age groups (18-50, 51-64, and â¥65 years). A) Longitudinal increases in spike antigen specific spot forming units per 10
                                <sup>
                                 6
                                </sup>
                                PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=17 18-50 year olds, n=9 51-64 year olds and n=9 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=18 18-50 year olds, n=8 51-64 year olds and n=10 â¥65 year olds). The right panel includes only participants with paired data available n=34 (n=19 18-50 year olds, n=8 51-64 year olds and n=7 â¥65 year olds), n=24 (n=10 18-50 year olds, n=7, 51-64 year olds and n=7 â¥65 year olds) and n=28 (n=14 18-50 year olds, n=5 51-64 year olds and n=9 â¥65 year olds) participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B) Example gating strategy for flow cytometry assays. C-D) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group (n=20 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds), n=35 participants in the 1.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds) and n=36 participants in the 2.0 mg dose group (n=19 18-50 year olds, n=10 51-64 year olds and n=10 â¥65 year olds). Open symbols represent individual participants, the box extends from the 25
                                <sup>
                                 th
                                </sup>
                                to the 75
                                <sup>
                                 th
                                </sup>
                                percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                             <div id="F4" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F4.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces cellular responses to SARS-CoV-2 Spike. A) Longitudinal increases in spike antigen specific spot forming units per 106 PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=30 and n=34 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B-C) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group and n=39 participants in the 1.0 mg and 2.0 mg dose groups. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml"><span class="caption-title">INO-4800 induces cellular responses to SARS-CoV-2 Spike.</span> A) Longitudinal increases in spike antigen specific spot forming units per 10<sup>6</sup> PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=30 and n=34 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B-C) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group and n=39 participants in the 1.0 mg and 2.0 mg dose groups. Open symbols represent individual participants, the box extends from the 25<sup>th</sup> to the 75<sup>th</sup> percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Figure 4" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F4.medium.gif" width="440" height="360"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Figure 4" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F4.medium.gif" width="440" height="360"/>
                                   </noscript>
                                  </span>
                                 </a>
                                </div>
                               </div>
                               <ul class="highwire-figure-links inline">
                                <li class="download-fig first">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F4.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 4" data-icon-position="" data-hide-link-title="0">
                                  Download figure
                                 </a>
                                </li>
                                <li class="new-tab last">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F4.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                  Open in new tab
                                 </a>
                                </li>
                               </ul>
                              </div>
                              <div class="fig-caption">
                               <span class="fig-label">
                                Figure 4
                               </span>
                               <span class="caption-title">
                                INO-4800 induces cellular responses to SARS-CoV-2 Spike.
                               </span>
                               <p id="p-55" class="first-child">
                                A) Longitudinal increases in spike antigen specific spot forming units per 10
                                <sup>
                                 6
                                </sup>
                                PBMCs over baseline in the IFN-g ELISpot are plotted. The left panel includes n=40 participants in the 0.5 mg dose group, n=35 participants in the 1.0 mg dose group and n=36 participants in the 2.0 mg dose group. The right panel includes n=31, n=30 and n=34 participants in the 0.5 mg, 1.0 mg, and 2.0 mg dose groups, respectively. B-C) Intracellular cytokine staining for IFN-g (purple) IL-2 (gray), TNF-a (blue) or any of the three cytokines (red) are plotted from samples collected at baseline or post-dose 2. The graphs include n=40 participants in the 0.5 mg dose group and n=39 participants in the 1.0 mg and 2.0 mg dose groups. Open symbols represent individual participants, the box extends from the 25
                                <sup>
                                 th
                                </sup>
                                to the 75
                                <sup>
                                 th
                                </sup>
                                percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by triangles (0.5 mg), circles (1.0 mg) and squares (2.0 mg).
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                            </div>
                            <div id="sec-25" class="subsection">
                             <h3>
                              INO-4800 induces cytokine producing T cells and activated CD8+T cells with lytic potential
                             </h3>
                             <p id="p-56">
                              The contribution of SARS-CoV-2 specific CD4
                              <sup>
                               +
                              </sup>
                              and CD8
                              <sup>
                               +
                              </sup>
                              T cells was assessed by intracellular cytokine staining (ICS) on participants following 2 doses,
                              <strong>
                               <a id="xref-fig-4-3" class="xref-fig" href="#F4">
                                Figure 4B-C
                               </a>
                              </strong>
                              . The median frequency of CD4+T cells producing IFNÎ³ increased following vaccination in all three dose groups of INO-4800, and the frequency of CD4+T cells producing TNFÎ± was statistically significantly increased in the 2.0 mg dose group (P<0.001) (
                              <strong>
                               <a id="xref-fig-4-4" class="xref-fig" href="#F4">
                                Figure 4B
                               </a>
                              </strong>
                              ). The frequency of CD8+T cells producing TNFÎ± was statistically significantly increased following vaccination in all three dose groups of INO-4800 (All Pâ¤0.041) (
                              <strong>
                               <a id="xref-fig-4-5" class="xref-fig" href="#F4">
                                Figure 4C
                               </a>
                              </strong>
                              ). The 2.0 mg dose group had the highest difference in medians for CD8+T cells producing any response, IFNÎ³ and TNFÎ± (0.066, 0.026, and 0.011 respectively). Responses by participant age are shown in
                              <strong>
                               <a id="xref-fig-8-2" class="xref-fig" href="#F8">
                                Supplementary Figure 3B-C
                               </a>
                               .
                              </strong>
                             </p>
                             <p id="p-57">
                              SARS-CoV-2 specific CD8+T cells were also characterized on a subset of participants with remaining sample following 3 doses by a flow cytometry assay that included activation markers CD69 and CD137. The median frequency of CD8+CD69+CD137+ cells increased following immunization with 2.0 mg of INO-4800, with a difference in the medians of 0.072
                              <strong>
                               (
                               <a id="xref-fig-5-1" class="xref-fig" href="#F5">
                                Figure 5A
                               </a>
                               , left panel)
                              </strong>
                              . Further characterization of these activated cells, including the co-expression of proteins utilized in cytolytic killing (granzyme A, granzyme B, perforin or granulysin) revealed a statistically significant increase in both the 1.0 mg (P=0.008) and 2.0 mg (P=0.003) dose groups
                              <strong>
                               (
                               <a id="xref-fig-5-2" class="xref-fig" href="#F5">
                                Figure 5A
                               </a>
                               middle and right panels).
                              </strong>
                              The 2.0 mg dose group had a difference in medians of 0.085 in the CD69+CD137+ population co-expressing perforin and granzymes A and B and 0.054 in the population co-expressing granulysin. CD8+T cells expressing the activation marker CD38 and proliferation marker Ki67 were also assessed
                              <strong>
                               (
                               <a id="xref-fig-5-3" class="xref-fig" href="#F5">
                                Figure 5B and C
                               </a>
                               , respectively).
                              </strong>
                              The frequency of SARS-CoV-2 specific CD38+CD8+T cells statistically significantly increased following 2.0 mg of INO-4800 (P=0.016), with a difference in medians of 1.45 (
                              <strong>
                               <a id="xref-fig-5-4" class="xref-fig" href="#F5">
                                Figure 5B
                               </a>
                               , left panel
                              </strong>
                              ). CD38+CD8+T cells with lytic potential (
                              <strong>
                               <a id="xref-fig-5-5" class="xref-fig" href="#F5">
                                Figure 5B
                               </a>
                               middle and right panels
                              </strong>
                              ) statistically significantly increased following 2.0 mg of INO-4800 (P<0.001). Following immunization with 2.0 mg of INO-4800, the mean frequency of activated CD8+T cells expressing granzymes A and B and perforin was 1.7% with a difference in medians of 0.710 and those expressing granulysin was 1.8% with a difference in medians of 0.433 (
                              <strong>
                               <a id="xref-fig-5-6" class="xref-fig" href="#F5">
                                Figure 5B
                               </a>
                               middle and right panels)
                              </strong>
                              . Statistically significant increases in the frequency of these CTL phenotypes were also observed in the 1.0 mg dose group (Pâ¤0.012) (
                              <strong>
                               <a id="xref-fig-5-7" class="xref-fig" href="#F5">
                                Figure 5B
                               </a>
                               middle and right panels
                              </strong>
                              ). The 2.0 mg dose group had the highest frequencies of CD8+T cells expressing Ki67 with a difference in medians of 0.367 and Ki67 with cytolytic proteins: 0.296 (GrzA+GrzB+Prf+) and 0.230 (Gnly+). All three Ki67+ populations were statistically significantly increased in the 2.0 mg dose group (Pâ¤0.001;
                              <strong>
                               <a id="xref-fig-5-8" class="xref-fig" href="#F5">
                                Figure 5C
                               </a>
                               )
                              </strong>
                              . The 2.0 mg dose group consistently showed the highest median responses across all phenotypes assessed compared to the other groups.
                             </p>
                             <div id="F5" class="fig pos-float type-figure odd">
                              <div class="highwire-figure">
                               <div class="fig-inline-img-wrapper">
                                <div class="fig-inline-img">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F5.large.jpg?width=800&height=600&carousel=1" title="INO-4800 induces spike specific activated CD8+T cells with lytic potential. A lytic granule loading flow cytometry assay was used to further characterize CD8+T cells and an example gating strategy is shown in (A). The expression of the activation markers CD69 and CD137 (B), CD38 (C), and the proliferation marker Ki67 (D) from samples collected at baseline or post-dose 2. The expression of proteins found in lytic granules: granzymes A (GrzA) and B (GrzB), perforin (Prf) and granulysin (Gnly) were assessed together with activation/proliferation subset. The graphs include n=4 participants in the 0.5 mg dose group and n=10 participants in the 1.0 mg dose group and n=13 in the 2.0 mg dose group. Open symbols represent individual participants, the box extends from the 25th to the 75th percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-1675270331" data-figure-caption='<div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml"><span class="caption-title">INO-4800 induces spike specific activated CD8+T cells with lytic potential.</span> A lytic granule loading flow cytometry assay was used to further characterize CD8+T cells and an example gating strategy is shown in (A). The expression of the activation markers CD69 and CD137 (B), CD38 (C), and the proliferation marker Ki67 (D) from samples collected at baseline or post-dose 2. The expression of proteins found in lytic granules: granzymes A (GrzA) and B (GrzB), perforin (Prf) and granulysin (Gnly) were assessed together with activation/proliferation subset. The graphs include n=4 participants in the 0.5 mg dose group and n=10 participants in the 1.0 mg dose group and n=13 in the 2.0 mg dose group. Open symbols represent individual participants, the box extends from the 25<sup>th</sup> to the 75<sup>th</sup> percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).</div></div>' data-icon-position="" data-hide-link-title="0">
                                  <span class="hw-responsive-img">
                                   <img class="highwire-fragment fragment-image lazyload" alt="Figure 5" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F5.medium.gif" width="440" height="360"/>
                                   <noscript>
                                    <img class="highwire-fragment fragment-image" alt="Figure 5" src="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F5.medium.gif" width="440" height="360"/>
                                   </noscript>
                                  </span>
                                 </a>
                                </div>
                               </div>
                               <ul class="highwire-figure-links inline">
                                <li class="download-fig first">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F5.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Figure 5" data-icon-position="" data-hide-link-title="0">
                                  Download figure
                                 </a>
                                </li>
                                <li class="new-tab last">
                                 <a href="https://www.medrxiv.org/content/medrxiv/early/2022/01/25/2021.10.06.21264584/F5.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">
                                  Open in new tab
                                 </a>
                                </li>
                               </ul>
                              </div>
                              <div class="fig-caption">
                               <span class="fig-label">
                                Figure 5
                               </span>
                               <span class="caption-title">
                                INO-4800 induces spike specific activated CD8+T cells with lytic potential.
                               </span>
                               <p id="p-58" class="first-child">
                                A lytic granule loading flow cytometry assay was used to further characterize CD8+T cells and an example gating strategy is shown in (A). The expression of the activation markers CD69 and CD137 (B), CD38 (C), and the proliferation marker Ki67 (D) from samples collected at baseline or post-dose 2. The expression of proteins found in lytic granules: granzymes A (GrzA) and B (GrzB), perforin (Prf) and granulysin (Gnly) were assessed together with activation/proliferation subset. The graphs include n=4 participants in the 0.5 mg dose group and n=10 participants in the 1.0 mg dose group and n=13 in the 2.0 mg dose group. Open symbols represent individual participants, the box extends from the 25
                                <sup>
                                 th
                                </sup>
                                to the 75
                                <sup>
                                 th
                                </sup>
                                percentile, line inside the box is the median, and the whiskers extend from the minimum to maximum values. The mean is denoted with a â+â sign. Wilcoxon signed-rank was used to assess significance versus baseline. The dose groups are represented by orange triangles (0.5 mg), blue circles (1.0 mg) and green squares (2.0 mg).
                               </p>
                               <div class="sb-div caption-clear">
                               </div>
                              </div>
                             </div>
                            </div>
                           </div>
                           <div class="section" id="sec-26">
                            <h2 class="">
                             Discussion
                            </h2>
                            <p id="p-59">
                             This report provides results for the expansion of a Phase 1 trial to include older and elderly participants and an optional booster dose with the aim to evaluate the safety, tolerability, and immunogenicity of INO-4800, a SARS-CoV-2 vaccine encoding the S protein[
                             <a id="xref-ref-14-8" class="xref-bibr" href="#ref-14">
                              14
                             </a>
                             ], including the immune responses 6 months following dose 2 and 2 weeks following the optional booster dose.
                            </p>
                            <p id="p-60">
                             INO-4800 appeared to be well-tolerated at all three dose levels, with no treatment-related serious adverse events (SAEs) reported. Most AEs were mild in severity and did not increase in frequency with age and subsequent dosing. These results are consistent with the severity of AEs and lack of treatment-related SAEs observed in the U.S. Phase 2 trial comparing the 1.0 mg and 2.0 mg doses of INO-4800 in approximately 400 subjects[
                             <a id="xref-ref-15-4" class="xref-bibr" href="#ref-15">
                              15
                             </a>
                             ] and those studies conducted outside the U.S. by Inovio collaborators (International Vaccine Institute, Advaccine â manuscripts in preparation). The lower frequency of treatment-related AEs reported by older and elderly participants in our study is consistent with findings of other studies evaluating SARS-CoV-2 vaccines[
                             <a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">
                              19
                             </a>
                             ,
                             <a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">
                              20
                             </a>
                             ]. Weaker inflammatory reactions consequent to immunosenescence may explain the lower incidence of AEs among elderly participants[
                             <a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">
                              21
                             </a>
                             ,
                             <a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">
                              22
                             </a>
                             ].
                            </p>
                            <p id="p-61">
                             Induction of both humoral and cellular responses were observed across all three dose groups, inclusive of binding and neutralizing antibodies and cytokine producing T cells as well as exhibiting lytic potential. Immunization with the 2.0 mg dose resulted in the highest GMTs of neutralizing and binding antibodies as well as the highest magnitudes of IFNÎ³ production to SARS-CoV-2 of any dose in all age groups tested, and the increases in antibody levels were statistically significant above baseline at 6 months following dose 2. Importantly, increases in both humoral and cellular immune responses were statistically significant following the booster dose.
                            </p>
                            <p id="p-62">
                             The contribution of the CD8+T cell response to vaccine efficacy has become increasingly recognized as they have been detected early after vaccination[
                             <a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">
                              23
                             </a>
                             ] and due to their role in controlling infection[
                             <a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">
                              24
                             </a>
                             ,
                             <a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">
                              25
                             </a>
                             ]. Specifically, it has been established that CD8+T cells expressing cytokines such as IFNÎ³ and TNFÎ± as well as markers involved in activation status and proliferation such as CD38 and Ki67 contribute to limiting disease severity during SARS-CoV-2 infection[
                             <a id="xref-ref-24-2" class="xref-bibr" href="#ref-24">
                              24
                             </a>
                             ]. Additional studies have identified the expression of CD69 and CD137 on SARS-CoV-2 specific CD8+T cells being associated with less severe disease[
                             <a id="xref-ref-25-2" class="xref-bibr" href="#ref-25">
                              25
                             </a>
                             ]. This expanded Phase 1 trial demonstrates that immunization with INO-4800 induces SARS-CoV-2 specific CD8+T cells exhibiting these specific characteristics, suggesting the induction of a vaccine-induced cellular response that has potential to protect against severe COVID-19. As VoCs continue to emerge, the generation of cross-reactive activated CD8+T cells with lytic potential is likely to play an important role in preventing severe disease. We have previously demonstrated that vaccination with INO-4800 induces T cells and neutralizing antibodies that are active against the parental SARS-CoV-2 strain as well as the B.1.1.7, B.1.351, and P.1 VoCs[
                             <a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">
                              26
                             </a>
                             ]. We acknowledge limitations to this trial that include the relatively small study population and the limited number of PBMCs available for testing across more than one assay. This trial was not powered to formally compare immune responses between dose groups or age stratifications. In addition, due to different immune assays and methodologies employed by various groups, it is not possible to directly compare immune responses observed in this trial to those elicited from other vaccine platforms or to determine if the magnitudes observed in this trial are sufficient to confer clinical benefit.
                            </p>
                            <p id="p-63">
                             The immune responses observed in the current trial and in our larger Phase 2 trial[
                             <a id="xref-ref-15-5" class="xref-bibr" href="#ref-15">
                              15
                             </a>
                             ] support advancing the 2.0 mg dose of INO-4800 to a Phase 3 efficacy evaluation. This dose has elicited the highest binding and neutralizing antibody titers, the highest T-cell cytokine production from both CD4+ and CD8+T cells, and the highest expression of markers associated with attenuation of severe COVID-19 on CD8+T cells.
                            </p>
                            <p id="p-64">
                             This trial demonstrated that immune responses elicited by a 2-dose primary series of INO-4800 could be boosted by a third dose without safety or tolerability concerns and positions INO-4800 as an important candidate for continued development as a stand-alone SARS-CoV-2 vaccine, as well as for continued examination in combination approaches. The potential ability to administer INO-4800 multiple times, with high tolerability, along with its ease of scalability and thermostability, contribute to its potential value in combatting the COVID-19 pandemic.
                            </p>
                           </div>
                           <div class="section COI-statement" id="sec-27">
                            <h2 class="">
                             Declaration of Interests
                            </h2>
                            <p id="p-65">
                             KAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received renumeration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.
                            </p>
                           </div>
                           <div class="section" id="sec-28">
                            <h2 class="">
                             Funding
                            </h2>
                            <p id="p-66">
                             This work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.
                            </p>
                           </div>
                           <div class="section data-availability" id="sec-29">
                            <h2 class="">
                             Data Availability
                            </h2>
                            <p id="p-67">
                             The preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing.
                            </p>
                           </div>
                           <div class="section" id="sec-30">
                            <h2 class="">
                             Supplementary Methods
                            </h2>
                            <div class="section" id="sec-31">
                             <h3>
                              Study Design and Enrollment Progression
                             </h3>
                             <p id="p-69">
                              Participants enrolled at one of three locations in the U.S.: The University of Pennsylvania Clinical Trials Unit in Philadelphia, PA; the Alliance for Multispecialty Research in Kansas City, MO; and the Alliance for Multispecialty Research in Lexington, KY.
                             </p>
                            </div>
                            <div class="section" id="sec-32">
                             <h3>
                              Assessment of SARS-CoV-2 Specific Immune Responses
                             </h3>
                             <div class="section" id="sec-33">
                              <h4>
                               SARS-CoV-2 Spike Enzyme-Linked Immunosorbent Assay (ELISA) description
                              </h4>
                              <p id="p-70">
                               Costar high bind plates were coated by incubating 1-3 days at 2-8Â°C with 2.0 Âµg/mL of recombinant SARS-CoV-2 spike protein trimer (Acro Biosystems; SPN-C52H9) which contains amino acids 16-1213 of the original Wuhan-Hu-1 isolate spike protein (ascension# QHD43416.1). The protein contains six proline substitutions for trimer stabilization and two alanine substitutions to eliminate the furin cleavage site. Coated plates were blocked with Starting Block (Thermo Scientific), followed by the addition of study samples, diluted 1/20 in Starting Block buffer. Plates were incubated for 1 hour, and then washed three times in PBS-tween. 1/1000-diluted anti-human IgG HRP conjugate (BD Pharmingen; 555788) was added, and plates were incubated for an additional hour. Plates were washed three times in PBS-tween, and SureBlue TMB substrate (SeraCare) was added. Assay plates were developed for approximately 9 minutes, and the color development was stopped by the addition of TMB Stop Solution (SeraCare).
                              </p>
                              <p id="p-71">
                               SARS-CoV-2 spike antibody concentrations were assigned to study samples by interpolation from a 4-parameter logistic model fit to a dilution curve of SARS-CoV-2 convalescent plasma. The convalescent plasma reference material (Aalto Bio Reagents Ltd) collected from a single convalescent donor >28 days after symptom onset from a PCR-confirmed SARS-CoV-2 test was arbitrarily assigned a concentration of 20,000 Units per mL. This sample was used as a control to standardize IgG responses across participant samples.
                              </p>
                             </div>
                             <div class="section" id="sec-34">
                              <h4>
                               SARS-CoV-2 Pseudovirus Neutralization Assay
                              </h4>
                              <p id="p-72">
                               Briefly, heat inactivated study serum samples were serially diluted and incubated for 90 minutes with a SARS-CoV-2-DeltaCT pseudovirus which is based on an HIV/luciferase reporter vector and expresses both SARS-CoV-2 spike protein and luciferase. After incubation, the pseudovirus/serum mixture was added to CHO target cells with stable ACE2 expression. After incubating the pseudovirus, serum, and cells together at 37Â°C for 72h, a britelite
                               <sup>
                                TM
                               </sup>
                               Plus luminescence reporter gene assay system (Perkin Elmer) was used to lyse cells and luminescence was measured using a Biotek plate reader.
                              </p>
                             </div>
                             <div class="section" id="sec-35">
                              <h4>
                               SARS-CoV-2 Spike ELISpot Assay Description
                              </h4>
                              <p id="p-73">
                               Briefly, 300,000 peripheral mononuclear cells (PBMCs) per well were stimulated overnight in triplicate wells of a pre-coated IFN-Î³ ELISpot plate (MabTech) using 200 ng per peptide per well (1 Âµg/mL per peptide final concentration) of a single peptide pool consisting of 15-mer peptides that overlapped by 9 residues and spanned the full-length spike protein. The next day, plates were developed as according to the manufacturerâs instructions (MabTech, Human IFN-g ELISpot Plus). A CTL S6 Micro Analyzer (CTL) with ImmunoCapture and ImmunoSpot software was used to scan and count spots corresponding to IFN-Î³ secreting cells. The ELISpot assay was performed in several batches due to the longevity of the study- the week 0 timepoint is run with each post-dose batch in order to have an appropriate baseline control. To most accurately represent the data, the baseline sample is subtracted from the post dose sample run in the same batch. The average of all week 0 values is 8.2 SFU/10
                               <sup>
                                6
                               </sup>
                               and the median is 3.3 SFU/10
                               <sup>
                                6
                               </sup>
                               .
                              </p>
                             </div>
                            </div>
                           </div>
                           <div class="section" id="sec-36">
                            <h2 class="">
                             Supplementary Data
                            </h2>
                            <div id="T2" class="table pos-float">
                             <div class="table-inline table-callout-links">
                              <div class="callout">
                               <span>
                                View this table:
                               </span>
                               <ul class="callout-links">
                                <li class="view-inline first">
                                 <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/467396/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">
                                  View inline
                                 </a>
                                </li>
                                <li class="view-popup">
                                 <a href="/highwire/markup/467396/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">
                                  View popup
                                 </a>
                                </li>
                                <li class="download-ppt last">
                                 <a href="/highwire/powerpoint/467396" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">
                                  Download powerpoint
                                 </a>
                                </li>
                               </ul>
                              </div>
                             </div>
                             <div class="table-caption">
                              <span class="table-label">
                               Supplementary Table 1:
                              </span>
                              <p id="p-74" class="first-child">
                               Geometric Mean Titers (GMT) in the pseudovirus neutralization assay
                              </p>
                              <div class="sb-div caption-clear">
                              </div>
                             </div>
                            </div>
                            <div id="T3" class="table pos-float">
                             <div class="table-inline table-callout-links">
                              <div class="callout">
                               <span>
                                View this table:
                               </span>
                               <ul class="callout-links">
                                <li class="view-inline first">
                                 <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/467397/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">
                                  View inline
                                 </a>
                                </li>
                                <li class="view-popup">
                                 <a href="/highwire/markup/467397/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">
                                  View popup
                                 </a>
                                </li>
                                <li class="download-ppt last">
                                 <a href="/highwire/powerpoint/467397" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">
                                  Download powerpoint
                                 </a>
                                </li>
                               </ul>
                              </div>
                             </div>
                             <div class="table-caption">
                              <span class="table-label">
                               Supplementary Table 2:
                              </span>
                              <p id="p-75" class="first-child">
                               Geometric Mean Titers (GMT) in ELISA
                              </p>
                              <div class="sb-div caption-clear">
                              </div>
                             </div>
                            </div>
                            <div id="T4" class="table pos-float">
                             <div class="table-inline table-callout-links">
                              <div class="callout">
                               <span>
                                View this table:
                               </span>
                               <ul class="callout-links">
                                <li class="view-inline first">
                                 <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/467401/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">
                                  View inline
                                 </a>
                                </li>
                                <li class="view-popup">
                                 <a href="/highwire/markup/467401/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">
                                  View popup
                                 </a>
                                </li>
                                <li class="download-ppt last">
                                 <a href="/highwire/powerpoint/467401" class="highwire-figure-link highwire-figure-link-ppt" data-icon-position="" data-hide-link-title="0">
                                  Download powerpoint
                                 </a>
                                </li>
                               </ul>
                              </div>
                             </div>
                             <div class="table-caption">
                              <span class="table-label">
                               Supplementary Table 3:
                              </span>
                              <p id="p-76" class="first-child">
                               Spike-specific SFU/10
                               <sup>
                                6
                               </sup>
                               PBMCs in the IFN-Î³ ELISpot assay
                              </p>
                              <div class="sb-div caption-clear">
                              </div>
                             </div>
                            </div>
                            <div id="T5" class="table pos-float">
                             <div class="table-inline table-callout-links">
                              <div class="callout">
                               <span>
                                View this table:
                               </span>
                               <ul class="callout-links">
                                <li class="view-inline first">
                                 <a href="##" class="table-expand-inline" data-table-url="/highwire/markup/467406/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed&table-expand-inline=1" data-icon-position="" data-hide-link-title="0">
                                  View inline
                                 </a>
                                </li>
                                <li class="view-popup last">
                                 <a href="/highwire/markup/467406/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed" class="colorbox colorbox-load table-expand-popup" rel="gallery-fragment-tables" data-icon-position="" data-hide-link-title="0">
                                  View popup
                                 </a>
                                </li>
                               </ul>
                              </div>
                             </div>
                             <div class="table-caption">
                              <span class="table-label">
                               Supplementary Table 4:
                              </span>
                              <p id="p-77" class="first-child">
                               <strong>
                                Summary of treatment-related Adverse Events by Age, Term, and Dose:
                               </strong>
                               Treatment related AEs were reported by A) twelve 18-50 year old participants (20%) reported B) five 51-64 year old participants (16.7%) and C) one â¥65 year old participant (3.3%). All AEs were Grade 1 (mild) in severity with the exception of Grade 2 (moderate) lethargy, abdominal pain, and injection site pruritus. In case of multiple events, a participant is counted only once per system organ class and once per preferred term.
                              </p>
                              <div class="sb-div caption-clear">
                              </div>
                             </div>
                            </div>
                           </div>
                           <div class="section ack" id="ack-1">
                            <h2 class="">
                             Acknowledgments
                            </h2>
                            <p id="p-68">
                             The investigators and sponsor express their gratitude for the contribution of all the trial participants and the invaluable advice of the independent Data Safety Monitoring Board. Feedback from the peer reviewers is gratefully acknowledged. We also acknowledge the broader support from the various teams within Inovio Pharmaceuticals (Ning Jiang, MD, PhD; Greta Kcomt Del Rio, BS; Alysia Ryan, BS; Dennis Van De Goor, MS; Kelly Morales, BS; Jacob Walton, BS; Srujan Vadlamudi, BS; David Valenta, PhD; EJ Brandreth, MBA; Dan Jordan, BS; Robert J. Juba Jr, MS; Stephen Kemmerrer, BSME, MBA, PE; Timothy Herring, MPH; Susan Duff, BS; and Prasad Kulkarni, PhD, CMPP), the Wistar Institute (Dr. Ziyang Xu and Edgar Tello Ruiz), the National Infections Service, Public Health England (Naomi Coombes, PhD and Mike Elmore, PhD), Hospital of the University of Pennsylvania (Joseph Quinn, RN), and the Alliance for Multispecialty Research, Kansas City, MO and Lexington, KY.
                            </p>
                           </div>
                           <div class="section fn-group" id="fn-group-1">
                            <h2>
                             Footnotes
                            </h2>
                            <ul>
                             <li class="fn-update fn-group-summary-of-updates" id="fn-2">
                              <p id="p-22">
                               Revisions made for clarification. Supplemental files updated.
                              </p>
                             </li>
                            </ul>
                           </div>
                           <div class="section ref-list" id="ref-list-1">
                            <h2 class="">
                             References
                            </h2>
                            <ol class="cit-list ref-use-labels">
                             <li>
                              <span class="ref-label">
                               1.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text" id="ref-1">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.1" data-doi="10.1056/nejmp2103614">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Katz
                                  </span>
                                  <span class="cit-name-given-names">
                                   IT
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Weintraub
                                  </span>
                                  <span class="cit-name-given-names">
                                   R
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Bekker
                                  </span>
                                  <span class="cit-name-given-names">
                                   LG
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Brandt
                                  </span>
                                  <span class="cit-name-given-names">
                                   AM
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  N Engl J Med
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  384
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  1281
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  3
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D384%26rft.spage%253D1281%26rft_id%253Dinfo%253Adoi%252F10.1056%252Fnejmp2103614%26rft_id%253Dinfo%253Apmid%252F33830709%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1056/nejmp2103614&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=33830709&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               2.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text" id="ref-2">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.2" data-doi="doi.org/10.1016/j.cell.2020.02.058">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Walls
                                  </span>
                                  <span class="cit-name-given-names">
                                   AC
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Park
                                  </span>
                                  <span class="cit-name-given-names">
                                   Y-J
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Tortorici
                                  </span>
                                  <span class="cit-name-given-names">
                                   MA
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Wall
                                  </span>
                                  <span class="cit-name-given-names">
                                   A
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   McGuire
                                  </span>
                                  <span class="cit-name-given-names">
                                   AT
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Veesler
                                  </span>
                                  <span class="cit-name-given-names">
                                   D.
                                  </span>
                                 </span>
                                 <span class="cit-article-title">
                                  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Cell
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  181
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  281
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  92
                                 </span>
                                 .e6.
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DCell%26rft.volume%253D181%26rft.spage%253D281%26rft_id%253Dinfo%253Adoi%252Fdoi.org%252F10.1016%252Fj.cell.2020.02.058%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=doi.org/10.1016/j.cell.2020.02.058&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               3.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text" id="ref-3">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.3" data-doi="10.1016/j.bbrc.2020.10.108">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Carrillo
                                  </span>
                                  <span class="cit-name-given-names">
                                   J
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Izquierdo-Useros
                                  </span>
                                  <span class="cit-name-given-names">
                                   N
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Avila-Nieto
                                  </span>
                                  <span class="cit-name-given-names">
                                   C
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Pradenas
                                  </span>
                                  <span class="cit-name-given-names">
                                   E
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Clotet
                                  </span>
                                  <span class="cit-name-given-names">
                                   B
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Blanco
                                  </span>
                                  <span class="cit-name-given-names">
                                   J
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Biochem Biophys Res Commun
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  538
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  187
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  91
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DBiochem%2BBiophys%2BRes%2BCommun%26rft.volume%253D538%26rft.spage%253D187%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.bbrc.2020.10.108%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1016/j.bbrc.2020.10.108&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               4.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text" id="ref-4">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.4">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Liu
                                  </span>
                                  <span class="cit-name-given-names">
                                   Q
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Qin
                                  </span>
                                  <span class="cit-name-given-names">
                                   C
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Liu
                                  </span>
                                  <span class="cit-name-given-names">
                                   M
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Liu
                                  </span>
                                  <span class="cit-name-given-names">
                                   J
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Infect Dis Poverty
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  10
                                 </span>
                                 :
                                 <span class="cit-issue">
                                  132
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               5.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text" id="ref-5">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.5">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Sharif
                                  </span>
                                  <span class="cit-name-given-names">
                                   N
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Alzahrani
                                  </span>
                                  <span class="cit-name-given-names">
                                   KJ
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Ahmed
                                  </span>
                                  <span class="cit-name-given-names">
                                   SN
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Dey
                                  </span>
                                  <span class="cit-name-given-names">
                                   SK.
                                  </span>
                                 </span>
                                 <span class="cit-article-title">
                                  Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Front Immunol
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  12
                                 </span>
                                 :
                                 <span class="cit-issue">
                                  714170
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               6.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text" id="ref-6">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.6" data-doi="10.1038/s41467-020-16505-0">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Smith
                                  </span>
                                  <span class="cit-name-given-names">
                                   TRF
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Patel
                                  </span>
                                  <span class="cit-name-given-names">
                                   A
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Ramos
                                  </span>
                                  <span class="cit-name-given-names">
                                   S
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Immunogenicity of a DNA vaccine candidate for COVID-19
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Nat Commun
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  11
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  2601
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DNat%2BCommun%26rft.volume%253D11%26rft.spage%253D2601%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41467-020-16505-0%26rft_id%253Dinfo%253Apmid%252F32433465%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1038/s41467-020-16505-0&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=32433465&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               7.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text" id="ref-7">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.7" data-doi="10.1016/j.coi.2020.01.006">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Gary
                                  </span>
                                  <span class="cit-name-given-names">
                                   EN
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Weiner
                                  </span>
                                  <span class="cit-name-given-names">
                                   DB
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  DNA vaccines: prime time is now
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Curr Opin Immunol
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  65
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  21
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  7
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DCurr%2BOpin%2BImmunol%26rft.volume%253D65%26rft.spage%253D21%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.coi.2020.01.006%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1016/j.coi.2020.01.006&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               8.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text" id="ref-8">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.8" data-doi="10.1016/j.xphs.2020.12.006">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Crommelin
                                  </span>
                                  <span class="cit-name-given-names">
                                   DJA
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Anchordoquy
                                  </span>
                                  <span class="cit-name-given-names">
                                   TJ
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Volkin
                                  </span>
                                  <span class="cit-name-given-names">
                                   DB
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Jiskoot
                                  </span>
                                  <span class="cit-name-given-names">
                                   W
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Mastrobattista
                                  </span>
                                  <span class="cit-name-given-names">
                                   E
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  Addressing the Cold Reality of mRNA Vaccine Stability
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  J Pharm Sci
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  110
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  997
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  1001
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DJ%2BPharm%2BSci%26rft.volume%253D110%26rft.spage%253D997%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.xphs.2020.12.006%26rft_id%253Dinfo%253Apmid%252F33321139%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1016/j.xphs.2020.12.006&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=33321139&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               9.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text" id="ref-9">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.9">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Liu
                                  </span>
                                  <span class="cit-name-given-names">
                                   MA
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Vaccines (Basel
                                 </abbr>
                                 )
                                 <span class="cit-pub-date">
                                  2019
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  7
                                 </span>
                                 :
                                 <span class="cit-issue">
                                  37
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               10.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text" id="ref-10">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.10" data-doi="10.1021/js970367a">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Middaugh
                                  </span>
                                  <span class="cit-name-given-names">
                                   CR
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Evans
                                  </span>
                                  <span class="cit-name-given-names">
                                   RK
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Montgomery
                                  </span>
                                  <span class="cit-name-given-names">
                                   DL
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Casimiro
                                  </span>
                                  <span class="cit-name-given-names">
                                   DR
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  Analysis of plasmid DNA from a pharmaceutical perspective
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  J Pharm Sci
                                 </abbr>
                                 <span class="cit-pub-date">
                                  1998
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  87
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  130
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  46
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bpharmaceutical%2Bsciences%26rft.stitle%253DJ%2BPharm%2BSci%26rft.aulast%253DMiddaugh%26rft.auinit1%253DC.%2BR.%26rft.volume%253D87%26rft.issue%253D2%26rft.spage%253D130%26rft.epage%253D146%26rft.atitle%253DAnalysis%2Bof%2Bplasmid%2BDNA%2Bfrom%2Ba%2Bpharmaceutical%2Bperspective.%26rft_id%253Dinfo%253Adoi%252F10.1021%252Fjs970367a%26rft_id%253Dinfo%253Apmid%252F9519144%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1021/js970367a&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=9519144&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=000071877300002&link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
                                 <span>
                                  Web of Science
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               11.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text" id="ref-11">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.11">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Patel
                                  </span>
                                  <span class="cit-name-given-names">
                                   A
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Walters
                                  </span>
                                  <span class="cit-name-given-names">
                                   J
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Reuschel
                                  </span>
                                  <span class="cit-name-given-names">
                                   EL
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  bioRxiv
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               12.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text" id="ref-12">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.12" data-doi="10.1016/j.vaccine.2021.06.057">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Gooch
                                  </span>
                                  <span class="cit-name-given-names">
                                   KE
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Smith
                                  </span>
                                  <span class="cit-name-given-names">
                                   TRF
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Salguero
                                  </span>
                                  <span class="cit-name-given-names">
                                   FJ
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Vaccine
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  39
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  4885
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  94
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DVaccine%26rft.volume%253D39%26rft.spage%253D4885%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.vaccine.2021.06.057%26rft_id%253Dinfo%253Apmid%252F34253420%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1016/j.vaccine.2021.06.057&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=34253420&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               13.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text" id="ref-13">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.13">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Walters
                                  </span>
                                  <span class="cit-name-given-names">
                                   JN
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Schouest
                                  </span>
                                  <span class="cit-name-given-names">
                                   B
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Patel
                                  </span>
                                  <span class="cit-name-given-names">
                                   A
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  bioRxiv
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 :2021.10.27.466163.
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               14.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text" id="ref-14">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.14">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Tebas
                                  </span>
                                  <span class="cit-name-given-names">
                                   P
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Yang
                                  </span>
                                  <span class="cit-name-given-names">
                                   S
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Boyer
                                  </span>
                                  <span class="cit-name-given-names">
                                   JD
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  EClinicalMedicine
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  31
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  100689
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DEClinicalMedicine%26rft.volume%253D31%26rft.spage%253D100689%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               15.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text" id="ref-15">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.15">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Mammen
                                  </span>
                                  <span class="cit-name-given-names">
                                   MP
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Tebas
                                  </span>
                                  <span class="cit-name-given-names">
                                   P
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Agnes
                                  </span>
                                  <span class="cit-name-given-names">
                                   J
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  medRxiv: the preprint server for health sciences
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 :2021.05.07.21256652.
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               16.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text" id="ref-16">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.16">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Tebas
                                  </span>
                                  <span class="cit-name-given-names">
                                   P
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Roberts
                                  </span>
                                  <span class="cit-name-given-names">
                                   CC
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Muthumani
                                  </span>
                                  <span class="cit-name-given-names">
                                   K
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  N Engl J Med
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2017
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               17.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text" id="ref-17">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.17">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Tebas
                                  </span>
                                  <span class="cit-name-given-names">
                                   P
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Kraynyak
                                  </span>
                                  <span class="cit-name-given-names">
                                   KA
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Patel
                                  </span>
                                  <span class="cit-name-given-names">
                                   A
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  J Infect Dis
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2019
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  220
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  400
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  10
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DJ%2BInfect%2BDis%26rft.volume%253D220%26rft.spage%253D400%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               18.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text" id="ref-18">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.18">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Aggarwal
                                  </span>
                                  <span class="cit-name-given-names">
                                   C
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Cohen
                                  </span>
                                  <span class="cit-name-given-names">
                                   RB
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Morrow
                                  </span>
                                  <span class="cit-name-given-names">
                                   MP
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Vaccines (Basel
                                 </abbr>
                                 )
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  8
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               19.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text" id="ref-19">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.19">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Chen
                                  </span>
                                  <span class="cit-name-given-names">
                                   M
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Yuan
                                  </span>
                                  <span class="cit-name-given-names">
                                   Y
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Zhou
                                  </span>
                                  <span class="cit-name-given-names">
                                   Y
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Infect Dis Poverty
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  10
                                 </span>
                                 :
                                 <span class="cit-issue">
                                  94
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               20.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text" id="ref-20">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.20">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Wu
                                  </span>
                                  <span class="cit-name-given-names">
                                   Q
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Dudley
                                  </span>
                                  <span class="cit-name-given-names">
                                   MZ
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Chen
                                  </span>
                                  <span class="cit-name-given-names">
                                   X
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Evaluation of the safety profile of COVID-19 vaccines: a rapid review
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  BMC Med
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  19
                                 </span>
                                 :
                                 <span class="cit-issue">
                                  173
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               21.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text" id="ref-21">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.21" data-doi="10.1038/nri2508">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Siegrist
                                  </span>
                                  <span class="cit-name-given-names">
                                   CA
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Aspinall
                                  </span>
                                  <span class="cit-name-given-names">
                                   R
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  B-cell responses to vaccination at the extremes of age
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Nature reviews Immunology
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2009
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  9
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  185
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  94
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DNature%2Breviews.%2BImmunology%26rft.stitle%253DNat%2BRev%2BImmunol%26rft.aulast%253DSiegrist%26rft.auinit1%253DC.%2BA.%26rft.volume%253D9%26rft.issue%253D3%26rft.spage%253D185%26rft.epage%253D194%26rft.atitle%253DB-cell%2Bresponses%2Bto%2Bvaccination%2Bat%2Bthe%2Bextremes%2Bof%2Bage.%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnri2508%26rft_id%253Dinfo%253Apmid%252F19240757%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=10.1038/nri2508&link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
                                 <span>
                                  CrossRef
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=19240757&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=000263677400013&link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
                                 <span>
                                  Web of Science
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               22.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text" id="ref-22">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.22">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Prelog
                                  </span>
                                  <span class="cit-name-given-names">
                                   M
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  Differential approaches for vaccination from childhood to old age
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Gerontology
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2013
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  59
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  230
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  9
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DGerontology%26rft.volume%253D59%26rft.spage%253D230%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               23.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text" id="ref-23">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.23">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Kalimuddin
                                  </span>
                                  <span class="cit-name-given-names">
                                   S
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Tham
                                  </span>
                                  <span class="cit-name-given-names">
                                   CYL
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Qui
                                  </span>
                                  <span class="cit-name-given-names">
                                   M
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Med (N Y
                                 </abbr>
                                 )
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  2
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  682
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  8
                                 </span>
                                 e4.
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DMed%2B%2528N%2BY%26rft.volume%253D2%26rft.spage%253D682%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               24.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text" id="ref-24">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.24">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Chen
                                  </span>
                                  <span class="cit-name-given-names">
                                   Z
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   John Wherry
                                  </span>
                                  <span class="cit-name-given-names">
                                   E
                                  </span>
                                 </span>
                                 .
                                 <span class="cit-article-title">
                                  T cell responses in patients with COVID-19
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Nature reviews Immunology
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  20
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  529
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  36
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DNature%2Breviews%2BImmunology%26rft.volume%253D20%26rft.spage%253D529%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               25.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25. in text" id="ref-25">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.25">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Rydyznski Moderbacher
                                  </span>
                                  <span class="cit-name-given-names">
                                   C
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Ramirez
                                  </span>
                                  <span class="cit-name-given-names">
                                   SI
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Dan
                                  </span>
                                  <span class="cit-name-given-names">
                                   JM
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  Cell
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2020
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  183
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  996
                                 </span>
                                 â
                                 <span class="cit-lpage">
                                  1012
                                 </span>
                                 e19.
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DCell%26rft.volume%253D183%26rft.spage%253D996%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                                <a href="/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F01%2F25%2F2021.10.06.21264584.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
                                 <span>
                                  PubMed
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                             <li>
                              <span class="ref-label">
                               26.
                              </span>
                              <a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26. in text" id="ref-26">
                               âµ
                              </a>
                              <div class="cit ref-cit ref-journal" id="cit-2021.10.06.21264584v2.26">
                               <div class="cit-metadata">
                                <cite>
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Andrade
                                  </span>
                                  <span class="cit-name-given-names">
                                   VM
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Christensen-Quick
                                  </span>
                                  <span class="cit-name-given-names">
                                   A
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-auth">
                                  <span class="cit-name-surname">
                                   Agnes
                                  </span>
                                  <span class="cit-name-given-names">
                                   J
                                  </span>
                                 </span>
                                 ,
                                 <span class="cit-etal">
                                  et al.
                                 </span>
                                 <span class="cit-article-title">
                                  INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
                                 </span>
                                 .
                                 <abbr class="cit-jnl-abbrev">
                                  NPJ Vaccines
                                 </abbr>
                                 <span class="cit-pub-date">
                                  2021
                                 </span>
                                 ;
                                 <span class="cit-vol">
                                  6
                                 </span>
                                 :
                                 <span class="cit-fpage">
                                  121
                                 </span>
                                 .
                                </cite>
                               </div>
                               <div class="cit-extra">
                                <a href="{openurl}?query=rft.jtitle%253DNPJ%2BVaccines%26rft.volume%253D6%26rft.spage%253D121%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
                                 <span>
                                  OpenUrl
                                 </span>
                                </a>
                               </div>
                              </div>
                             </li>
                            </ol>
                           </div>
                           <span class="highwire-journal-article-marker-end">
                           </span>
                          </div>
                          <span class="related-urls">
                          </span>
                         </div>
                        </div>
                       </div>
                      </div>
                     </div>
                    </div>
                   </div>
                  </div>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-disqus-comment">
                <div class="pane-content">
                 <div id="disqus_thread">
                  <noscript>
                   <p>
                    <a href="http://medRxiv.disqus.com/?url=https%3A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.1101%2F2021.10.06.21264584v2" class="" data-icon-position="" data-hide-link-title="0">
                     View the discussion thread.
                    </a>
                   </p>
                  </noscript>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-highwire-back-to-top">
                <div class="pane-content">
                 <a href="#page" class="back-to-top" data-icon-position="" data-hide-link-title="0">
                  <span class="icon-chevron-up">
                  </span>
                  Back to top
                 </a>
                </div>
               </div>
              </div>
             </div>
            </div>
            <div class="sidebar-right-wrapper grid-10 omega">
             <div class="panel-panel panel-region-sidebar-right">
              <div class="inside">
               <div class="panel-pane pane-highwire-node-pager">
                <div class="pane-content">
                 <div class="pager highwire-pager pager-mini clearfix highwire-node-pager highwire-article-pager">
                  <span class="pager-prev">
                   <a href="/content/10.1101/2021.06.07.21258225v3" title="Health-related quality of life of female sex workers living with HIV in South Africa: a cross-sectional study" rel="prev" class="pager-link-prev link-icon">
                    <span class="icon-circle-arrow-left">
                    </span>
                    <span class="title">
                     Previous
                    </span>
                   </a>
                  </span>
                  <span class="pager-next">
                   <a href="/content/10.1101/2021.11.22.21266673v2" title="Neutralization of SARS-CoV-2 variants by rVSV-ÎG-spike-elicited human sera" rel="next" class="pager-link-next link-icon-right link-icon">
                    <span class="title">
                     Next
                    </span>
                    <span class="icon-circle-arrow-right">
                    </span>
                   </a>
                  </span>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-custom pane-1">
                <div class="pane-content">
                 PostedÂ January 25, 2022.
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-panels-mini pane-biorxiv-art-tools">
                <div class="pane-content">
                 <div id="mini-panel-biorxiv_art_tools" class="highwire-2col-stacked panel-display">
                  <div class="panel-row-wrapper clearfix">
                   <div class="content-left-wrapper content-column">
                    <div class="panel-panel panel-region-content-left">
                     <div class="inside">
                      <div class="panel-pane pane-highwire-variant-link">
                       <div class="pane-content">
                        <a href="/content/10.1101/2021.10.06.21264584v2.full.pdf" target="_self" class="article-dl-pdf-link link-icon">
                         <span class="icon-external-link-sign">
                         </span>
                         <span class="title">
                          Download PDF
                         </span>
                        </a>
                       </div>
                      </div>
                      <div class="panel-separator">
                      </div>
                      <div class="panel-pane pane-highwire-variant-link">
                       <div class="pane-content">
                        <a href="/content/early/2022/01/25/2021.10.06.21264584.external-links" target="_self" class="link-icon">
                         <span class="icon-file">
                         </span>
                         <span class="title">
                          Data/Code
                         </span>
                        </a>
                       </div>
                      </div>
                     </div>
                    </div>
                   </div>
                   <div class="content-right-wrapper content-column">
                    <div class="panel-panel panel-region-content-right">
                     <div class="inside">
                      <div class="panel-pane pane-minipanel-dialog-link pane-biorxiv-art-email">
                       <div class="pane-content">
                        <div class="minipanel-dialog-wrapper">
                         <div class="minipanel-dialog-link-link">
                          <a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger" title="Email this Article" data-icon-position="" data-hide-link-title="0">
                           <i class="icon-envelope">
                           </i>
                           Email
                          </a>
                         </div>
                         <div class="minipanel-dialog-link-mini" style="display:none">
                          <div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_art_email">
                           <div class="panel-panel panel-col">
                            <div>
                             <div class="panel-pane pane-block pane-forward-form pane-forward">
                              <div class="pane-content">
                               <form action="/content/10.1101/2021.10.06.21264584v2.full" method="post" id="forward-form" accept-charset="UTF-8">
                                <div>
                                 <div id="edit-instructions" class="form-item form-item-label-before form-type-item">
                                  <p>
                                   Thank you for your interest in spreading the word about medRxiv.
                                  </p>
                                  <p>
                                   NOTE: Your email address is requested solely to identify you as the sender of this article.
                                  </p>
                                 </div>
                                 <div class="form-item form-item-label-before form-type-textfield form-item-email">
                                  <label for="edit-email">
                                   Your Email
                                   <span class="form-required" title="This field is required.">
                                    *
                                   </span>
                                  </label>
                                  <input type="text" id="edit-email" name="email" value="" size="58" maxlength="256" class="form-text required"/>
                                 </div>
                                 <div class="form-item form-item-label-before form-type-textfield form-item-name">
                                  <label for="edit-name">
                                   Your Name
                                   <span class="form-required" title="This field is required.">
                                    *
                                   </span>
                                  </label>
                                  <input type="text" id="edit-name" name="name" value="" size="58" maxlength="256" class="form-text required"/>
                                 </div>
                                 <div class="form-item form-item-label-before form-type-textarea form-item-recipients">
                                  <label for="edit-recipients">
                                   Send To
                                   <span class="form-required" title="This field is required.">
                                    *
                                   </span>
                                  </label>
                                  <div class="form-textarea-wrapper resizable">
                                   <textarea id="edit-recipients" name="recipients" cols="50" rows="5" class="form-textarea required"></textarea>
                                  </div>
                                  <div class="description">
                                   Enter multiple addresses on separate lines or separate them with commas.
                                  </div>
                                 </div>
                                 <div id="edit-page" class="form-item form-item-label-before form-type-item">
                                  <label for="edit-page">
                                   You are going to email the following
                                  </label>
                                  <a href="/content/10.1101/2021.10.06.21264584v2" class="active" data-icon-position="" data-hide-link-title="0">
                                   SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
                                  </a>
                                 </div>
                                 <div id="edit-subject" class="form-item form-item-label-before form-type-item">
                                  <label for="edit-subject">
                                   Message Subject
                                  </label>
                                  (Your Name) has forwarded a page to you from medRxiv
                                 </div>
                                 <div id="edit-body" class="form-item form-item-label-before form-type-item">
                                  <label for="edit-body">
                                   Message Body
                                  </label>
                                  (Your Name) thought you would like to see this page from the medRxiv website.
                                 </div>
                                 <div class="form-item form-item-label-before form-type-textarea form-item-message">
                                  <label for="edit-message--2">
                                   Your Personal Message
                                  </label>
                                  <div class="form-textarea-wrapper resizable">
                                   <textarea id="edit-message--2" name="message" cols="50" rows="10" class="form-textarea"></textarea>
                                  </div>
                                 </div>
                                 <input type="hidden" name="path" value="node/465813"/>
                                 <input type="hidden" name="path_cid" value=""/>
                                 <input type="hidden" name="forward_footer" value=" "/>
                                 <input type="hidden" name="form_build_id" value="form-w_Zo0IOlBTghUgNppBJr77Dn_5efZcMagaVETRMPuIc"/>
                                 <input type="hidden" name="form_id" value="forward_form"/>
                                 <fieldset class="captcha form-wrapper">
                                  <legend>
                                   <span class="fieldset-legend">
                                    CAPTCHA
                                   </span>
                                  </legend>
                                  <div class="fieldset-wrapper">
                                   <div class="fieldset-description">
                                    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
                                   </div>
                                   <input type="hidden" name="captcha_sid" value="277160396"/>
                                   <input type="hidden" name="captcha_token" value="20222d4c81909d60dbe3e412aaa2c6af"/>
                                   <input type="hidden" name="captcha_response" value="Google no captcha"/>
                                   <div class="g-recaptcha" data-sitekey="6LfnJVIUAAAAAE-bUOMg0MJGki4lqSvDmhJp19fN" data-theme="light" data-type="image">
                                   </div>
                                  </div>
                                 </fieldset>
                                 <div class="form-actions form-wrapper" id="edit-actions">
                                  <input type="submit" id="edit-submit" name="op" value="Send Message" class="form-submit"/>
                                 </div>
                                </div>
                               </form>
                              </div>
                             </div>
                            </div>
                           </div>
                          </div>
                         </div>
                        </div>
                       </div>
                      </div>
                      <div class="panel-separator">
                      </div>
                      <div class="panel-pane pane-highwire-share-link highwire_clipboard_link_ajax" id="shareit">
                       <div class="pane-content">
                        <a href="/" class="link-icon">
                         <span class="icon-share-alt">
                         </span>
                         <span class="title">
                          Share
                         </span>
                        </a>
                       </div>
                      </div>
                      <div class="panel-separator">
                      </div>
                      <div class="panel-pane pane-panels-mini pane-biorxiv-share highwire_clipboard_form_ajax_shareit">
                       <div class="pane-content">
                        <div class="panel-display omega-12-onecol" id="mini-panel-biorxiv_share">
                         <div class="panel-panel grid-12 panel-region-preface">
                          <div class="inside">
                           <div class="panel-pane pane-highwire-article-citation">
                            <div class="pane-content">
                             <div class="highwire-article-citation highwire-citation-type-highwire-article node465813--3" data-node-nid="465813" id="node-465813--41978824878" data-pisa="medrxiv;2021.10.06.21264584v2" data-pisa-master="medrxiv;2021.10.06.21264584" data-seqnum="465813" data-apath="/medrxiv/early/2022/01/25/2021.10.06.21264584.atom">
                              <div class="highwire-cite highwire-cite-highwire-article highwire-citation-biorxiv-article-pap-list clearfix">
                               <div class="highwire-cite-title">
                                <div class="highwire-cite-title">
                                 SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
                                </div>
                               </div>
                               <div class="highwire-cite-authors">
                                <span class="highwire-citation-authors">
                                 <span class="highwire-citation-author first" data-delta="0">
                                  <span class="nlm-given-names">
                                   Kimberly A.
                                  </span>
                                  <span class="nlm-surname">
                                   Kraynyak
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="1">
                                  <span class="nlm-given-names">
                                   Elliott
                                  </span>
                                  <span class="nlm-surname">
                                   Blackwood
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="2">
                                  <span class="nlm-given-names">
                                   Joseph
                                  </span>
                                  <span class="nlm-surname">
                                   Agnes
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="3">
                                  <span class="nlm-given-names">
                                   Pablo
                                  </span>
                                  <span class="nlm-surname">
                                   Tebas
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="4">
                                  <span class="nlm-given-names">
                                   Mary
                                  </span>
                                  <span class="nlm-surname">
                                   Giffear
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="5">
                                  <span class="nlm-given-names">
                                   Dinah
                                  </span>
                                  <span class="nlm-surname">
                                   Amante
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="6">
                                  <span class="nlm-given-names">
                                   Emma L.
                                  </span>
                                  <span class="nlm-surname">
                                   Reuschel
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="7">
                                  <span class="nlm-given-names">
                                   Mansi
                                  </span>
                                  <span class="nlm-surname">
                                   Purwar
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="8">
                                  <span class="nlm-given-names">
                                   Aaron
                                  </span>
                                  <span class="nlm-surname">
                                   Christensen-Quick
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="9">
                                  <span class="nlm-given-names">
                                   Neiman
                                  </span>
                                  <span class="nlm-surname">
                                   Liu
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="10">
                                  <span class="nlm-given-names">
                                   Viviane M.
                                  </span>
                                  <span class="nlm-surname">
                                   Andrade
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="11">
                                  <span class="nlm-given-names">
                                   Malissa C.
                                  </span>
                                  <span class="nlm-surname">
                                   Diehl
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="12">
                                  <span class="nlm-given-names">
                                   Snehal
                                  </span>
                                  <span class="nlm-surname">
                                   Wani
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="13">
                                  <span class="nlm-given-names">
                                   Martyna
                                  </span>
                                  <span class="nlm-surname">
                                   Lupicka
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="14">
                                  <span class="nlm-given-names">
                                   Albert
                                  </span>
                                  <span class="nlm-surname">
                                   Sylvester
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="15">
                                  <span class="nlm-given-names">
                                   Matthew P.
                                  </span>
                                  <span class="nlm-surname">
                                   Morrow
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="16">
                                  <span class="nlm-given-names">
                                   Patrick
                                  </span>
                                  <span class="nlm-surname">
                                   Pezzoli
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="17">
                                  <span class="nlm-given-names">
                                   Trevor
                                  </span>
                                  <span class="nlm-surname">
                                   McMullan
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="18">
                                  <span class="nlm-given-names">
                                   Abhijeet J.
                                  </span>
                                  <span class="nlm-surname">
                                   Kulkarni
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="19">
                                  <span class="nlm-given-names">
                                   Faraz I.
                                  </span>
                                  <span class="nlm-surname">
                                   Zaidi
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="20">
                                  <span class="nlm-given-names">
                                   Drew
                                  </span>
                                  <span class="nlm-surname">
                                   Frase
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="21">
                                  <span class="nlm-given-names">
                                   Kevin
                                  </span>
                                  <span class="nlm-surname">
                                   Liaw
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="22">
                                  <span class="nlm-given-names">
                                   Trevor R.F.
                                  </span>
                                  <span class="nlm-surname">
                                   Smith
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="23">
                                  <span class="nlm-given-names">
                                   Stephanie J.
                                  </span>
                                  <span class="nlm-surname">
                                   Ramos
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="24">
                                  <span class="nlm-given-names">
                                   John
                                  </span>
                                  <span class="nlm-surname">
                                   Ervin
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="25">
                                  <span class="nlm-given-names">
                                   Mark
                                  </span>
                                  <span class="nlm-surname">
                                   Adams
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="26">
                                  <span class="nlm-given-names">
                                   Jessica
                                  </span>
                                  <span class="nlm-surname">
                                   Lee
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="27">
                                  <span class="nlm-given-names">
                                   Michael
                                  </span>
                                  <span class="nlm-surname">
                                   Dallas
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="28">
                                  <span class="nlm-given-names">
                                   Ami Shah
                                  </span>
                                  <span class="nlm-surname">
                                   Brown
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="29">
                                  <span class="nlm-given-names">
                                   Jacqueline E.
                                  </span>
                                  <span class="nlm-surname">
                                   Shea
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="30">
                                  <span class="nlm-given-names">
                                   J. Joseph
                                  </span>
                                  <span class="nlm-surname">
                                   Kim
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="31">
                                  <span class="nlm-given-names">
                                   David B.
                                  </span>
                                  <span class="nlm-surname">
                                   Weiner
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="32">
                                  <span class="nlm-given-names">
                                   Kate E.
                                  </span>
                                  <span class="nlm-surname">
                                   Broderick
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="33">
                                  <span class="nlm-given-names">
                                   Laurent M.
                                  </span>
                                  <span class="nlm-surname">
                                   Humeau
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="34">
                                  <span class="nlm-given-names">
                                   Jean D.
                                  </span>
                                  <span class="nlm-surname">
                                   Boyer
                                  </span>
                                 </span>
                                 ,
                                 <span class="highwire-citation-author" data-delta="35">
                                  <span class="nlm-given-names">
                                   Mammen P.
                                  </span>
                                  <span class="nlm-surname">
                                   Mammen
                                  </span>
                                  <span class="nlm-suffix">
                                   Jr.
                                  </span>
                                 </span>
                                </span>
                               </div>
                               <div class="highwire-cite-metadata">
                                <span class="highwire-cite-metadata-journal highwire-cite-metadata">
                                 medRxiv
                                </span>
                                <span class="highwire-cite-metadata-pages highwire-cite-metadata">
                                 2021.10.06.21264584;
                                </span>
                                <span class="highwire-cite-metadata-doi highwire-cite-metadata">
                                 <span class="doi_label">
                                  doi:
                                 </span>
                                 https://doi.org/10.1101/2021.10.06.21264584
                                </span>
                               </div>
                              </div>
                             </div>
                            </div>
                           </div>
                          </div>
                         </div>
                         <div class="panel-panel grid-12 panel-region-content">
                          <div class="inside">
                           <div class="panel-pane pane-highwire-article-clipboard-copy">
                            <div class="pane-content">
                             <div class="clipboard-copy">
                              <span class="label-url">
                               <label for="dynamic">
                                Share This Article:
                               </label>
                              </span>
                              <span class="input-text-url">
                               <input type="text" id="dynamic" value="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2" size="50"/>
                              </span>
                              <span class="copy-button button">
                               <button id="copy-dynamic" class="clipboardjs-button" data-clipboard-target="#dynamic" data-clipboard-alert-style="tooltip" data-clipboard-alert-text="Copied!">
                                Copy
                               </button>
                              </span>
                             </div>
                            </div>
                           </div>
                          </div>
                         </div>
                         <div class="panel-panel grid-12 panel-region-postscript">
                          <div class="inside">
                           <div class="panel-pane pane-service-links">
                            <div class="pane-content">
                             <div class="service-links">
                              <a href="http://digg.com/submit?phase=2&url=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&title=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial" id="digg" title="Digg this post on digg.com" class="service-links-digg" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/digg.png" alt="Digg logo"/>
                              </a>
                              <a href="http://reddit.com/submit?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&title=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial" id="reddit" title="Submit this post on reddit.com" class="service-links-reddit" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/reddit.png" alt="Reddit logo"/>
                              </a>
                              <a href="http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&text=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial" id="twitter" title="Share this on Twitter" class="service-links-twitter" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png" alt="Twitter logo"/>
                              </a>
                              <a href="http://www.facebook.com/sharer.php?u=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&t=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial" id="facebook" title="Share on Facebook" class="service-links-facebook" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png" alt="Facebook logo"/>
                              </a>
                              <a href="http://www.google.com/bookmarks/mark?op=add&bkmk=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&title=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial" id="google" title="Bookmark this post on Google" class="service-links-google" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/google-32.png" alt="Google logo"/>
                              </a>
                              <a href="http://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&title=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial&summary=&source=medRxiv" id="linkedin" title="Publish this post to LinkedIn" class="service-links-linkedin" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png" alt="LinkedIn logo"/>
                              </a>
                              <a href="http://www.mendeley.com/import/?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&title=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial" id="mendeley" title="Share on Mendeley" class="service-links-mendeley" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                               <img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png" alt="Mendeley logo"/>
                              </a>
                             </div>
                            </div>
                           </div>
                          </div>
                         </div>
                        </div>
                       </div>
                      </div>
                      <div class="panel-separator">
                      </div>
                      <div class="panel-pane pane-minipanel-dialog-link pane-biorxiv-cite-tool">
                       <div class="pane-content">
                        <div class="minipanel-dialog-wrapper">
                         <div class="minipanel-dialog-link-link">
                          <a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger link-icon" title="Citation Tools">
                           <span class="icon-globe">
                           </span>
                           <span class="title">
                            Citation Tools
                           </span>
                          </a>
                         </div>
                         <div class="minipanel-dialog-link-mini" style="display:none">
                          <div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_cite_tool">
                           <div class="panel-panel panel-col">
                            <div>
                             <div class="panel-pane pane-highwire-citation-export">
                              <div class="pane-content">
                               <div class="highwire-citation-export">
                                <div class="highwire-citation-info">
                                 <div class="highwire-article-citation highwire-citation-type-highwire-article cite-tool-node465813--5" data-node-nid="465813" id="citation-node-465813--62070591905" data-pisa="medrxiv;2021.10.06.21264584v2" data-pisa-master="medrxiv;2021.10.06.21264584" data-seqnum="465813" data-apath="/medrxiv/early/2022/01/25/2021.10.06.21264584.atom">
                                  <div class="highwire-cite highwire-cite-highwire-article highwire-citation-biorxiv-article-pap-list clearfix">
                                   <div class="highwire-cite-title">
                                    <div class="highwire-cite-title">
                                     SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
                                    </div>
                                   </div>
                                   <div class="highwire-cite-authors">
                                    <span class="highwire-citation-authors">
                                     <span class="highwire-citation-author first" data-delta="0">
                                      <span class="nlm-given-names">
                                       Kimberly A.
                                      </span>
                                      <span class="nlm-surname">
                                       Kraynyak
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="1">
                                      <span class="nlm-given-names">
                                       Elliott
                                      </span>
                                      <span class="nlm-surname">
                                       Blackwood
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="2">
                                      <span class="nlm-given-names">
                                       Joseph
                                      </span>
                                      <span class="nlm-surname">
                                       Agnes
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="3">
                                      <span class="nlm-given-names">
                                       Pablo
                                      </span>
                                      <span class="nlm-surname">
                                       Tebas
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="4">
                                      <span class="nlm-given-names">
                                       Mary
                                      </span>
                                      <span class="nlm-surname">
                                       Giffear
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="5">
                                      <span class="nlm-given-names">
                                       Dinah
                                      </span>
                                      <span class="nlm-surname">
                                       Amante
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="6">
                                      <span class="nlm-given-names">
                                       Emma L.
                                      </span>
                                      <span class="nlm-surname">
                                       Reuschel
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="7">
                                      <span class="nlm-given-names">
                                       Mansi
                                      </span>
                                      <span class="nlm-surname">
                                       Purwar
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="8">
                                      <span class="nlm-given-names">
                                       Aaron
                                      </span>
                                      <span class="nlm-surname">
                                       Christensen-Quick
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="9">
                                      <span class="nlm-given-names">
                                       Neiman
                                      </span>
                                      <span class="nlm-surname">
                                       Liu
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="10">
                                      <span class="nlm-given-names">
                                       Viviane M.
                                      </span>
                                      <span class="nlm-surname">
                                       Andrade
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="11">
                                      <span class="nlm-given-names">
                                       Malissa C.
                                      </span>
                                      <span class="nlm-surname">
                                       Diehl
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="12">
                                      <span class="nlm-given-names">
                                       Snehal
                                      </span>
                                      <span class="nlm-surname">
                                       Wani
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="13">
                                      <span class="nlm-given-names">
                                       Martyna
                                      </span>
                                      <span class="nlm-surname">
                                       Lupicka
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="14">
                                      <span class="nlm-given-names">
                                       Albert
                                      </span>
                                      <span class="nlm-surname">
                                       Sylvester
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="15">
                                      <span class="nlm-given-names">
                                       Matthew P.
                                      </span>
                                      <span class="nlm-surname">
                                       Morrow
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="16">
                                      <span class="nlm-given-names">
                                       Patrick
                                      </span>
                                      <span class="nlm-surname">
                                       Pezzoli
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="17">
                                      <span class="nlm-given-names">
                                       Trevor
                                      </span>
                                      <span class="nlm-surname">
                                       McMullan
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="18">
                                      <span class="nlm-given-names">
                                       Abhijeet J.
                                      </span>
                                      <span class="nlm-surname">
                                       Kulkarni
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="19">
                                      <span class="nlm-given-names">
                                       Faraz I.
                                      </span>
                                      <span class="nlm-surname">
                                       Zaidi
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="20">
                                      <span class="nlm-given-names">
                                       Drew
                                      </span>
                                      <span class="nlm-surname">
                                       Frase
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="21">
                                      <span class="nlm-given-names">
                                       Kevin
                                      </span>
                                      <span class="nlm-surname">
                                       Liaw
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="22">
                                      <span class="nlm-given-names">
                                       Trevor R.F.
                                      </span>
                                      <span class="nlm-surname">
                                       Smith
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="23">
                                      <span class="nlm-given-names">
                                       Stephanie J.
                                      </span>
                                      <span class="nlm-surname">
                                       Ramos
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="24">
                                      <span class="nlm-given-names">
                                       John
                                      </span>
                                      <span class="nlm-surname">
                                       Ervin
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="25">
                                      <span class="nlm-given-names">
                                       Mark
                                      </span>
                                      <span class="nlm-surname">
                                       Adams
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="26">
                                      <span class="nlm-given-names">
                                       Jessica
                                      </span>
                                      <span class="nlm-surname">
                                       Lee
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="27">
                                      <span class="nlm-given-names">
                                       Michael
                                      </span>
                                      <span class="nlm-surname">
                                       Dallas
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="28">
                                      <span class="nlm-given-names">
                                       Ami Shah
                                      </span>
                                      <span class="nlm-surname">
                                       Brown
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="29">
                                      <span class="nlm-given-names">
                                       Jacqueline E.
                                      </span>
                                      <span class="nlm-surname">
                                       Shea
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="30">
                                      <span class="nlm-given-names">
                                       J. Joseph
                                      </span>
                                      <span class="nlm-surname">
                                       Kim
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="31">
                                      <span class="nlm-given-names">
                                       David B.
                                      </span>
                                      <span class="nlm-surname">
                                       Weiner
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="32">
                                      <span class="nlm-given-names">
                                       Kate E.
                                      </span>
                                      <span class="nlm-surname">
                                       Broderick
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="33">
                                      <span class="nlm-given-names">
                                       Laurent M.
                                      </span>
                                      <span class="nlm-surname">
                                       Humeau
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="34">
                                      <span class="nlm-given-names">
                                       Jean D.
                                      </span>
                                      <span class="nlm-surname">
                                       Boyer
                                      </span>
                                     </span>
                                     ,
                                     <span class="highwire-citation-author" data-delta="35">
                                      <span class="nlm-given-names">
                                       Mammen P.
                                      </span>
                                      <span class="nlm-surname">
                                       Mammen
                                      </span>
                                      <span class="nlm-suffix">
                                       Jr.
                                      </span>
                                     </span>
                                    </span>
                                   </div>
                                   <div class="highwire-cite-metadata">
                                    <span class="highwire-cite-metadata-journal highwire-cite-metadata">
                                     medRxiv
                                    </span>
                                    <span class="highwire-cite-metadata-pages highwire-cite-metadata">
                                     2021.10.06.21264584;
                                    </span>
                                    <span class="highwire-cite-metadata-doi highwire-cite-metadata">
                                     <span class="doi_label">
                                      doi:
                                     </span>
                                     https://doi.org/10.1101/2021.10.06.21264584
                                    </span>
                                   </div>
                                  </div>
                                 </div>
                                </div>
                                <div class="highwire-citation-formats">
                                 <h2>
                                  Citation Manager Formats
                                 </h2>
                                 <div class="highwire-citation-formats-links">
                                  <span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.spage&rft.epage&rft.atitle=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial&rft.volume&rft.issue&rft.date=2022-01-01%2000%3A00%3A00&rft.stitle&rft.jtitle=medRxiv&rft.au=Kraynyak%2C+Kimberly+A.&rft.au=Blackwood%2C+Elliott&rft.au=Agnes%2C+Joseph&rft.au=Tebas%2C+Pablo&rft.au=Giffear%2C+Mary&rft.au=Amante%2C+Dinah&rft.au=Reuschel%2C+Emma+L.&rft.au=Purwar%2C+Mansi&rft.au=Christensen-Quick%2C+Aaron&rft.au=Liu%2C+Neiman&rft.au=Andrade%2C+Viviane+M.&rft.au=Diehl%2C+Malissa+C.&rft.au=Wani%2C+Snehal&rft.au=Lupicka%2C+Martyna&rft.au=Sylvester%2C+Albert&rft.au=Morrow%2C+Matthew+P.&rft.au=Pezzoli%2C+Patrick&rft.au=McMullan%2C+Trevor&rft.au=Kulkarni%2C+Abhijeet+J.&rft.au=Zaidi%2C+Faraz+I.&rft.au=Frase%2C+Drew&rft.au=Liaw%2C+Kevin&rft.au=Smith%2C+Trevor+R.F.&rft.au=Ramos%2C+Stephanie+J.&rft.au=Ervin%2C+John&rft.au=Adams%2C+Mark&rft.au=Lee%2C+Jessica&rft.au=Dallas%2C+Michael&rft.au=Brown%2C+Ami+Shah&rft.au=Shea%2C+Jacqueline+E.&rft.au=Kim%2C+J.+Joseph&rft.au=Weiner%2C+David+B.&rft.au=Broderick%2C+Kate+E.&rft.au=Humeau%2C+Laurent+M.&rft.au=Boyer%2C+Jean+D.&rft.au=Mammen%2C+Mammen+P.">
                                  </span>
                                  <ul class="hw-citation-links inline button button-alt button-grid clearfix">
                                   <li class="bibtext first">
                                    <a href="/highwire/citation/465813/bibtext" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     BibTeX
                                    </a>
                                   </li>
                                   <li class="bookends">
                                    <a href="/highwire/citation/465813/bookends" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     Bookends
                                    </a>
                                   </li>
                                   <li class="easybib">
                                    <a href="/highwire/citation/465813/easybib" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     EasyBib
                                    </a>
                                   </li>
                                   <li class="endnote-tagged">
                                    <a href="/highwire/citation/465813/endnote-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     EndNote (tagged)
                                    </a>
                                   </li>
                                   <li class="endnote-8-xml">
                                    <a href="/highwire/citation/465813/endnote-8-xml" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     EndNote 8 (xml)
                                    </a>
                                   </li>
                                   <li class="medlars">
                                    <a href="/highwire/citation/465813/medlars" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     Medlars
                                    </a>
                                   </li>
                                   <li class="mendeley">
                                    <a href="/highwire/citation/465813/mendeley" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     Mendeley
                                    </a>
                                   </li>
                                   <li class="papers">
                                    <a href="/highwire/citation/465813/papers" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     Papers
                                    </a>
                                   </li>
                                   <li class="refworks-tagged">
                                    <a href="/highwire/citation/465813/refworks-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     RefWorks Tagged
                                    </a>
                                   </li>
                                   <li class="reference-manager">
                                    <a href="/highwire/citation/465813/reference-manager" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     Ref Manager
                                    </a>
                                   </li>
                                   <li class="ris">
                                    <a href="/highwire/citation/465813/ris" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     RIS
                                    </a>
                                   </li>
                                   <li class="zotero last">
                                    <a href="/highwire/citation/465813/zotero" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">
                                     Zotero
                                    </a>
                                   </li>
                                  </ul>
                                 </div>
                                </div>
                               </div>
                              </div>
                             </div>
                            </div>
                           </div>
                          </div>
                         </div>
                        </div>
                       </div>
                      </div>
                     </div>
                    </div>
                   </div>
                  </div>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-service-links">
                <div class="pane-content">
                 <div class="service-links">
                  <div class="item-list">
                   <ul>
                    <li class="first">
                     <a href="http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&count=horizontal&via=&text=SARS-CoV-2%20DNA%20Vaccine%20INO-4800%20Induces%20Durable%20Immune%20Responses%20Capable%20of%20Being%20Boosted%20in%20a%20Phase%201%20Open-Label%20Trial&counturl=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2" class="twitter-share-button service-links-twitter-widget" id="twitter_widget" title="Tweet This" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                      <span class="element-invisible">
                       Tweet Widget
                      </span>
                     </a>
                    </li>
                    <li>
                     <a href="http://www.facebook.com/plugins/like.php?href=https%3A//www.medrxiv.org/content/10.1101/2021.10.06.21264584v2&layout=button_count&show_faces=false&action=like&colorscheme=light&width=100&height=21&font=&locale=" id="facebook_like" title="I Like it" class="service-links-facebook-like" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                      <span class="element-invisible">
                       Facebook Like
                      </span>
                     </a>
                    </li>
                    <li class="last">
                     <a href="https://www.medrxiv.org/content/10.1101/2021.10.06.21264584v2" id="google_plus_one" title="Plus it" class="service-links-google-plus-one" rel="nofollow" data-icon-position="" data-hide-link-title="0">
                      <span class="element-invisible">
                       Google Plus One
                      </span>
                     </a>
                    </li>
                   </ul>
                  </div>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-highwire-article-collections">
                <h2 class="pane-title">
                 Subject Area
                </h2>
                <div class="pane-content">
                 <div class="highwire-list-wrapper highwire-article-collections">
                  <div class="highwire-list">
                   <ul class="highwire-article-collection-term-list">
                    <li class="first last odd">
                     <span class="highwire-article-collection-term">
                      <a href="/collection/infectious_diseases" class="highlight" data-icon-position="" data-hide-link-title="0">
                       Infectious Diseases (except HIV/AIDS)
                       <i class="icon-caret-right">
                       </i>
                      </a>
                     </span>
                    </li>
                   </ul>
                  </div>
                 </div>
                </div>
               </div>
               <div class="panel-separator">
               </div>
               <div class="panel-pane pane-panels-mini pane-biorxiv-subject-collections block-style-col2">
                <div class="pane-content">
                 <div class="panel-flexible panels-flexible-new clearfix" id="mini-panel-biorxiv_subject_collections">
                  <div class="panel-flexible-inside panels-flexible-new-inside">
                   <div class="panels-flexible-region panels-flexible-region-new-center panels-flexible-region-first panels-flexible-region-last">
                    <div class="inside panels-flexible-region-inside panels-flexible-region-new-center-inside panels-flexible-region-inside-first panels-flexible-region-inside-last">
                     <div class="panel-pane pane-snippet">
                      <div class="pane-content">
                       <div class="snippet biorxiv-subject-areas-table-title" id="biorxiv-subject-areas-table-title">
                        <div class="snippet-content">
                         <b>
                          Subject Areas
                         </b>
                        </div>
                       </div>
                      </div>
                     </div>
                     <div class="panel-separator">
                     </div>
                     <div class="panel-pane pane-snippet">
                      <div class="pane-content">
                       <div class="snippet biorxiv-subject-areas-view-papers" id="biorxiv-subject-areas-view-papers">
                        <div class="snippet-content">
                         <a href="/content/early/recent">
                          <strong>
                           All Articles
                          </strong>
                         </a>
                        </div>
                       </div>
                      </div>
                     </div>
                     <div class="panel-separator">
                     </div>
                     <div class="panel-pane pane-highwire-subject-collections">
                      <div class="pane-content">
                       <ul id="collection" class="collection highwire-list-expand">
                        <li class="outer collection depth-2 child first">
                         <div class="data-wrapper">
                          <a href="/collection/addiction-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Addiction Medicine
                          </a>
                          <span class="article-count">
                           (218)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/allergy-and-immunology" class="" data-icon-position="" data-hide-link-title="0">
                           Allergy and Immunology
                          </a>
                          <span class="article-count">
                           (496)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/anesthesia" class="" data-icon-position="" data-hide-link-title="0">
                           Anesthesia
                          </a>
                          <span class="article-count">
                           (106)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/cardiovascular-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Cardiovascular Medicine
                          </a>
                          <span class="article-count">
                           (1121)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/dentistry-and-oral-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Dentistry and Oral Medicine
                          </a>
                          <span class="article-count">
                           (198)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/dermatology" class="" data-icon-position="" data-hide-link-title="0">
                           Dermatology
                          </a>
                          <span class="article-count">
                           (141)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/emergency-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Emergency Medicine
                          </a>
                          <span class="article-count">
                           (275)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease" class="" data-icon-position="" data-hide-link-title="0">
                           Endocrinology (including Diabetes Mellitus and Metabolic Disease)
                          </a>
                          <span class="article-count">
                           (510)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/epidemiology" class="" data-icon-position="" data-hide-link-title="0">
                           Epidemiology
                          </a>
                          <span class="article-count">
                           (9829)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/forensic-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Forensic Medicine
                          </a>
                          <span class="article-count">
                           (5)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/gastroenterology" class="" data-icon-position="" data-hide-link-title="0">
                           Gastroenterology
                          </a>
                          <span class="article-count">
                           (484)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/genetic-and-genomic-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Genetic and Genomic Medicine
                          </a>
                          <span class="article-count">
                           (2344)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/geriatric-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Geriatric Medicine
                          </a>
                          <span class="article-count">
                           (225)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/health-economics" class="" data-icon-position="" data-hide-link-title="0">
                           Health Economics
                          </a>
                          <span class="article-count">
                           (465)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/health-informatics" class="" data-icon-position="" data-hide-link-title="0">
                           Health Informatics
                          </a>
                          <span class="article-count">
                           (1574)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/health-policy" class="" data-icon-position="" data-hide-link-title="0">
                           Health Policy
                          </a>
                          <span class="article-count">
                           (738)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/health-systems-and-quality-improvement" class="" data-icon-position="" data-hide-link-title="0">
                           Health Systems and Quality Improvement
                          </a>
                          <span class="article-count">
                           (609)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/hematology" class="" data-icon-position="" data-hide-link-title="0">
                           Hematology
                          </a>
                          <span class="article-count">
                           (239)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/hiv-aids" class="" data-icon-position="" data-hide-link-title="0">
                           HIV/AIDS
                          </a>
                          <span class="article-count">
                           (510)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/infectious_diseases" class="" data-icon-position="" data-hide-link-title="0">
                           Infectious Diseases (except HIV/AIDS)
                          </a>
                          <span class="article-count">
                           (11686)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/intensive-care-and-critical-care-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Intensive Care and Critical Care Medicine
                          </a>
                          <span class="article-count">
                           (617)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/medical-education" class="" data-icon-position="" data-hide-link-title="0">
                           Medical Education
                          </a>
                          <span class="article-count">
                           (242)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/medical-ethics" class="" data-icon-position="" data-hide-link-title="0">
                           Medical Ethics
                          </a>
                          <span class="article-count">
                           (67)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/nephrology" class="" data-icon-position="" data-hide-link-title="0">
                           Nephrology
                          </a>
                          <span class="article-count">
                           (259)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/neurology" class="" data-icon-position="" data-hide-link-title="0">
                           Neurology
                          </a>
                          <span class="article-count">
                           (2170)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/nursing" class="" data-icon-position="" data-hide-link-title="0">
                           Nursing
                          </a>
                          <span class="article-count">
                           (134)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/nutrition" class="" data-icon-position="" data-hide-link-title="0">
                           Nutrition
                          </a>
                          <span class="article-count">
                           (340)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/obstetrics-and-gynecology" class="" data-icon-position="" data-hide-link-title="0">
                           Obstetrics and Gynecology
                          </a>
                          <span class="article-count">
                           (427)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/occupational-and-environmental-health" class="" data-icon-position="" data-hide-link-title="0">
                           Occupational and Environmental Health
                          </a>
                          <span class="article-count">
                           (521)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/oncology" class="" data-icon-position="" data-hide-link-title="0">
                           Oncology
                          </a>
                          <span class="article-count">
                           (1188)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/ophthalmology" class="" data-icon-position="" data-hide-link-title="0">
                           Ophthalmology
                          </a>
                          <span class="article-count">
                           (368)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/orthopedics" class="" data-icon-position="" data-hide-link-title="0">
                           Orthopedics
                          </a>
                          <span class="article-count">
                           (129)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/otolaryngology" class="" data-icon-position="" data-hide-link-title="0">
                           Otolaryngology
                          </a>
                          <span class="article-count">
                           (221)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/pain-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Pain Medicine
                          </a>
                          <span class="article-count">
                           (148)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/palliative-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Palliative Medicine
                          </a>
                          <span class="article-count">
                           (50)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/pathology" class="" data-icon-position="" data-hide-link-title="0">
                           Pathology
                          </a>
                          <span class="article-count">
                           (315)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/pediatrics" class="" data-icon-position="" data-hide-link-title="0">
                           Pediatrics
                          </a>
                          <span class="article-count">
                           (702)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/pharmacology-and-therapeutics" class="" data-icon-position="" data-hide-link-title="0">
                           Pharmacology and Therapeutics
                          </a>
                          <span class="article-count">
                           (304)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/primary-care-research" class="" data-icon-position="" data-hide-link-title="0">
                           Primary Care Research
                          </a>
                          <span class="article-count">
                           (269)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/psychiatry-and-clinical-psychology" class="" data-icon-position="" data-hide-link-title="0">
                           Psychiatry and Clinical Psychology
                          </a>
                          <span class="article-count">
                           (2201)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/public-and-global-health" class="" data-icon-position="" data-hide-link-title="0">
                           Public and Global Health
                          </a>
                          <span class="article-count">
                           (4705)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/radiology-and-imaging" class="" data-icon-position="" data-hide-link-title="0">
                           Radiology and Imaging
                          </a>
                          <span class="article-count">
                           (786)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/rehabilitation-medicine-and-physical-therapy" class="" data-icon-position="" data-hide-link-title="0">
                           Rehabilitation Medicine and Physical Therapy
                          </a>
                          <span class="article-count">
                           (462)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/respiratory-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Respiratory Medicine
                          </a>
                          <span class="article-count">
                           (626)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/rheumatology" class="" data-icon-position="" data-hide-link-title="0">
                           Rheumatology
                          </a>
                          <span class="article-count">
                           (276)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/sexual-and-reproductive-health" class="" data-icon-position="" data-hide-link-title="0">
                           Sexual and Reproductive Health
                          </a>
                          <span class="article-count">
                           (227)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/sports-medicine" class="" data-icon-position="" data-hide-link-title="0">
                           Sports Medicine
                          </a>
                          <span class="article-count">
                           (214)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/surgery" class="" data-icon-position="" data-hide-link-title="0">
                           Surgery
                          </a>
                          <span class="article-count">
                           (254)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/toxicology" class="" data-icon-position="" data-hide-link-title="0">
                           Toxicology
                          </a>
                          <span class="article-count">
                           (43)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child">
                         <div class="data-wrapper">
                          <a href="/collection/transplantation" class="" data-icon-position="" data-hide-link-title="0">
                           Transplantation
                          </a>
                          <span class="article-count">
                           (121)
                          </span>
                         </div>
                        </li>
                        <li class="outer collection depth-2 child last">
                         <div class="data-wrapper">
                          <a href="/collection/urology" class="" data-icon-position="" data-hide-link-title="0">
                           Urology
                          </a>
                          <span class="article-count">
                           (94)
                          </span>
                         </div>
                        </li>
                       </ul>
                      </div>
                     </div>
                    </div>
                   </div>
                  </div>
                 </div>
                </div>
               </div>
              </div>
             </div>
            </div>
           </div>
          </div>
         </div>
        </div>
       </div>
      </div>
     </div>
    </div>
   </section>
  </div>
  <div class="region region-page-bottom" id="region-page-bottom">
   <div class="region-inner region-page-bottom-inner">
   </div>
  </div>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__VNH5GD8Zz7g6_hGCOZjVjdMndxxC6naiExSSJKX3k_A__kzmEdtbqCsJx5Z9yg2Qy0PptB__ufXm-TxUOl0KZzUw__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js">
  </script>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__2WRbxlwOW0MEUc_hSWU5MBepQg6Lch6O5SZwefpJ6IE__HCL0YQJqLkOhrLPZZYGqosGvtFsEHMGghHIkSx4y9vA__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js" defer="defer">
  </script>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__N7ERJBYsOWyRnJgyoM125_Aiez2MOJGaUofG1JdWWBg__2cpwCQ7-xzTVeVvg_KOzwA1jka23oWApDPpgjoZKDCY__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js">
  </script>
  <script type="text/javascript" src="https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.js">
  </script>
  <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__BmqjBnkz3MgYCAoc25s1lDRMEjLhC3mEPVonUFIHi08__Unwv5-ZIuHBfFwytsjEx1niBVJ7n1T4lPws7VrkHXM4__yDRjOTiBnSnu2tzh2xbnVTigKcZk0CFMqnf6m8vMg3M.js">
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
function euCookieComplianceLoadScripts() {}
//--&gt;&lt;!]]&gt;
  </script>
  <script type="text/javascript">
   &lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
var eu_cookie_compliance_cookie_name = "";
//--&gt;&lt;!]]&gt;
  </script>
 </body>
</html>
